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The increasing threat of antibiotic resistant pathogens is a major problem in the 
management of infectious diseases, making it imperative that new antibiotics to combat 
them are discovered and sourced. However, limiting work to merely discovering these 
novel antibiotics is far too narrow of a scope. It is equally important to understand how 
the biochemistry and production of these secondary metabolites is regulated. 
Furthermore, a better understanding of the bioactivity and structure of novel variants of 
secondary metabolites may lead to the identification of products with enhanced 
properties, such as improved spectrum of activity or reduced minimum inhibitory 
concentrations. 
Using a member of the Burkholderia cepacia complex, Burkholderia 
contaminans MS14, my dissertation studies have been aimed at identifying novel 
antimicrobial factors and to gain a better understanding of the antimicrobial secondary 
metabolites the bacterium is capable of producing. The Burkholderia genus is highly 
conserved; therefore many of the insights gleaned from its study could be applied to 
other members of its genus. This includes the more virulent strains such as Burkholderia 
cepacia and Burkholderia pseudomallei. My work led to the identification of a novel 
antibacterial produced by B. contaminans MS14. In these studies, it was discovered that 
MS14 also produces ornibactin, a powerful siderophore. Siderophores are commonly 
associated with iron acquisition. However, the most interesting aspect was not the 




antibacterial product. Thus we learned that ornibactin, rather than just being an 
additional product with minor antibacterial properties, has a direct effect on the 
antimicrobial capabilities of B. contaminans MS14. My studies clearly show an 
alternative function for this siderophore, as knockout strains that lacked the ability to 
make ornibactin completely lost bactericidal activity. While this antimicrobial product 
proved difficult to isolate, I was able to investigate and report several of its inherent 
properties, such as its estimated size, polarity, and stability. Interestingly, this product is 
highly resistant to common forms of damage, such as temperature and pH. However, 
direct UV exposure resulted in the destruction of this antibiotic, giving clues into its 
physical structure.  
Occidiofungin is a novel lipopeptide that is a potent anticandidal fungicide and 
exhibits its mode of action by binding to actin, resulting in apoptosis. However, in 
addition several variants are also produced. Studies on the isolation of these different 
variants of occidiofungin have led to the discovery of a new product. Due to their 
potency against opportunistic pathogens of both humans and plants, these variants are 
possible candidates for medical or agricultural applications. In addition to the known 
variants, the discovery of a novel variant and the further structural elucidation of the 
compound using nuclear magnetic resonance, suggests that the non-ribosomal peptide 
synthetase (NRPS) module for diamino butyric acid has some promiscuity for other 
amino acids. Additional information pertaining to its spectrum of activity and 
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1.1 The antimicrobial activity of Burkholderia species 
The world is continually facing the growing problem of antibiotic resistant 
bacteria and fungi. As of this writing, data from the Centers for Disease Control and 
Prevention (CDC) shows that each year over two million people are infected with an 
antibiotic resistant pathogen. Of these two million, these infections prove to be fatal in 
more than twenty-three thousand cases (1). More alarming still is the fact that these 
numbers are not a worldwide figure, but instead are only in cases within the United 
States.   This continually rising threat has a broader scope than just medical concerns as 
they also increase the financial burden laid upon the individual, if they’re fortunate 
enough to have healthcare. Recent estimates have found that patients infected with a 
bacterial or fungal pathogen that is antibiotic resistant can expect an increase of $1,383 
to their treatment cost. This amounts to an additional nationwide cost of $2.2 billion 
each year on top of already existing expenditures (2).  
When presented with information regarding antibiotic resistant pathogens, it is 
logical to assume that an average individual would only consider the threat they present 
as infectious agents in the human population. However, it is essential that when 
examining and addressing this concern efforts are also made to include the danger 
present to a nation’s agriculture as well. This particular danger is multifaceted: not only 
is it possible for contaminated products to reach nationwide public consumption, but 




resistance to current treatments. These infections could lead to poor yields or outright 
crop loss, which in turn would have consequences that reverberate throughout the 
economy. Additionally, the strain placed upon maintaining a sustainable food supply 
should not be overlooked; there are numerous historical examples that demonstrate how 
devastating a rampant infection in agriculture could have on a nation, such as the Great 
Famine in Ireland during the 1840’s (3), or more recent threats such as Race Ug99 (4). It 
is vital to remember that antibiotic resistant pathogens will not discriminate when it 
comes to infection. 
Without new drugs to treat illnesses caused by these pathogens, we will not only 
face increasing treatment costs, but ultimately we will reach a point where our current 
stable of last resort drugs is driven to the point of ineffectiveness. Compounding this 
problem is the slow rate of discovery of new antibiotics: there is only so much a chemist 
in a lab can do when it comes to synthesizing new solutions. In the modern age of 
medicine we live in, it can be easy to forget that nature has been in the business of 
antimicrobial agents for a lot longer than we have (5) . In the search for novel 
antimicrobials, investigating for new medicinal candidates is not just limited to naturally 
occurring sources such as plants as one might expect but from microbes such as bacteria 
themselves, which are actually the source of most clinically available antibiotics. 
Understandably, when most people think of natural selection and the idea of 
“survival of the fittest,” there is a tendency to apply these concepts solely to creatures 
which have easily observable competitive traits. These traits, such as size, speed and 




for resources. However, superior fitness extends from the largest creatures down to the 
smallest, such as microorganisms. There are numerous ways that bacteria in particular 
compete with neighboring microbes for nutrients and growth territory, such as having a 
higher numbers when compared to their competitors. Among these means there are 
numerous bacteria that produce secondary metabolites that halt the growth or kill 
outright the rival microorganisms in their local ecosystem. One such bacterium belongs 
to the genus Burkholderia.  
Burkholderia is a Gram-negative, non-sporulating genus which, while ubiquitous 
and capable of growing within plants and groundwater, it is primarily a soil-dwelling 
bacterium. It derives its name from Walter H. Burkholder, who first encountered the 
organism in 1950 while investigating disease in young onion crops (6). At the time it 
was grouped with the genus Pseudomonas, but due to advances in genetic tools it was 
determined that it was more accurate to consider this a close relationship rather than a 
shared identity. This decision was made based on the 16S rRNA sequences, DNA-DNA 
homology values, cellular lipid and fatty acid composition, and phenotypic 
characteristics. As a result, in 1992 seven species were split from Pseudomonas 
Homology Group II and given its new designation of Burkholderia (7). As of this 
writing, this number now resides at 122 different species of Burkholderia that have been 
published or reported on (8). While this review will be focusing on the antimicrobial 
capabilities of the Burkholderia genus, some attention should be given to what are likely 




trepidation: which are the potentially life-threatening illnesses caused by Burkholderia 
mallei, Burkholderia pseudomallei, and Burkholderia cepacia. 
 
1.2 Burkholderia mallei and Burkholderia pseudomallei 
While all three of the aforementioned species carry the genus name coined in 
1992, knowledge of the organisms and their effects on humans, crops, and livestock are 
far from recent. This is especially true of Burkholderia mallei, which causes glanders. 
This infectious disease has been chronicled in ancient history, as the Greek physician 
Hippocrates first described its effects on equine species in 425 BCE (9). While primarily 
an infectious agent observed in livestock, human transmission is possible and its 
symptoms and severity is largely the same, regardless of the species unfortunate enough 
to contract the disease. In either case, the most common effects are observed in the upper 
respiratory tract, where chronic discharge, lesions and ulcers can appear. If untreated at 
this stage, B. mallei can increase its severity to an acute infection that causes septicemia. 
At this stage, glanders have a mortality rate up to 90% in as little as 7 to 10 days in 
untreated individuals (10). Due to the lack of recent cases in almost all well-developed 
countries, in addition to the initial symptoms being quite similar to pneumonia or the flu, 
it is conceivable that an infected individual would not seek proper treatment or may even 
be misdiagnosed, leading to an increased chance at the infection spreading to the 
bloodstream. Even in instances where adequate medical attention and the correct 
antibiotics are administered, the threat posed to those infected still remains alarmingly 




Furthermore, the devastation and disruption that B. mallei could cause in warfare has not 
gone unnoticed as well, with German troops using it as a weapon to disrupt horse and 
mule-driven supply lines in World War I, and Japanese forces purposely infecting 
prisoners, civilians and livestock in the Pacific Theater of World War II (11).   
Despite the severity of infection and the possibility of transmission to humans, 
actual infections in the human populace are extremely rare, with transmission rates also 
being comparably low. Furthermore, human-to-human transmission has never been 
reported in the United States (12, 13). Both of these facts are likely due to an atypical 
characteristic of B. mallei: it is an obligate mammalian pathogen. In essence this means 
that outside of laboratory conditions it cannot be found in the soil, water, or plants one 
would expect in other Burkholderia species, and instead it is only found in infected 
hosts. However, because in the rare event of a human infection manifesting in dangerous 
symptoms and a high mortality in untreated cases, as well as its capability of being 
transmitted through inhalation, Burkholderia mallei has been assigned a classification as 
a biosafety level 3 agent, with 4 being the highest level an organism can be assigned. In 
addition to this, and its history of having been used in warfare, the Centers for Disease 
Control and Prevention considers B. mallei a candidate for being developed into a 
bioterrorism weapon and have thus classified it as a Category B disease-causing 
organism. This is the second highest classification the CDC has (14); for comparison, 
threats in this category includes cholera and ricin. 
Contrary to B. mallei, Burkholderia pseudomallei is found in its typical 




Northern Australia (15). This particular species of Burkholderia is most well-known for 
causing melioidosis (also sometimes referred to as Whitmore’s disease). Melioidosis 
infections most frequently occur when an individual or livestock comes into contact with 
soil or standing water contaminated with B. pseudomallei, often through cuts or 
abrasions on the skin, however infections in the lungs can occur through the inhalation if 
these sources are aerosolized (13). The largest danger with regards to a melioidosis 
infection is two-fold: it is capable of multiple infection sites (localized, pulmonary, and 
septic) and, similar to an infection with B. mallei, can be difficult to initially diagnose. 
Further complications arise due to the initial symptoms appearing flu like, with common 
pneumonia or possibly a tuberculosis infection being the most typical diseases 
melioidosis is mistaken for. Completely untreated, melioidosis has a mortality rate as 
high as 90%; however a basic course of antibiotic treatment drastically lowers this 
number. Even though B. pseudomallei is naturally resistant to antibiotics due to the 
presence of efflux pumps, the treatments that do exist for individuals who contract 
melioidosis cause the mortality rate to drop to less than 40%, and this number falls even 
further to less than 20% for those that seek more intensive treatment options. This, along 
with the fact that human-to-human transmission of melioidosis is extremely rare could 
lend credence to an argument that the threat of B. pseudomallei is not very high, 
however this is not the case (16). Both Burkholderia pseudomallei  and glanders share 
the common traits of possible infection through inhalation, nor having a vaccine to 
prevent initial infection (17). This, as well as the fact that closely related B. mallei has 




classifying its possible danger. As such, B. pseudomallei shares the same level of 
classification: it is a biosafety level 3 organism that is also considered a Category B 
threat by the CDC.  
While Burkholderia mallei and pseudomallei are the only members of the genus 
that are direct causative agents of disease in non-immunocompromised individuals, the 
severity of their safety classifications has led to most of the remaining members of the 
genus being classified as biosafety level 2 organisms. This classification could be 
considered inaccurate for many species of Burkholderia, as numerous examples exist 
that are completely avirulent, such as Burkholderia thailandensis. This species is closely 
related to Burkholderia pseudomallei, but requires a 1000-fold increase in dosage to 
reach lethal levels (18). Still, there exists one remaining group of Burkholderia that 
poses a threat as human-infectious agents, and that is Burkholderia cepacia and the 
species closely related to it. 
 
1.2.1 The Burkholderia cepacia complex (BCC) 
Despite the two previously described species having a much longer history in 
regards to disease and warfare, the most infamous member of the Burkholderia genus is 
likely Burkholderia cepacia, due to its occurrence and complications in modern 
medicine. Although not particularly virulent on its own B. cepacia has gained notoriety 
as a colonizer in the respiratory airways of immunocompromised patients, particularly 
those with cystic fibrosis, with the first reported case occurring in 1977 (19). Due to the 




growth environment for bacteria. The infections quickly become chronic and are 
eventually cleared through antibiotic treatment; however each subsequent infection 
leaves behind increasing amounts of scar tissue. The accumulation off scar tissue is what 
eventually contributes to respiratory failure and death in CF patients. 
The Burkholderia cepacia complex itself was designated in 1997, when samples 
of the namesake bacterium species were isolated from cystic fibrosis patients and 
recognized as having five distinct genomic species (20). As of today, there are at least 
nine recognized genomovars containing at least 20 closely‐related species (21). Of all 
the species included within the BCC, Burkholderia cenocepacia has risen as the most 
deadly of the species. Although there are some other members of the BCC that can cause 
severe infections the reported mortality rate is still lower than that of B. cenocepacia 
(22). Despite Burkholderia cepacia being the first species of the genus found in an 
infected cystic fibrosis lung, the species most prevalent in CF patients are B. 
cenocepacia and B. multivorans, with B. cepacia now being found most commonly 
among patients with a non-CF associated lung infection (23).  
Given the serious nature of the disease and infections caused by the 
aforementioned Burkholderia species one can easily understand why it would not be a 
researcher’s first choice when learning about its non-virulent properties.  However, 
despite being as severe as a biosafety level 3 organism it is important to acknowledge 
that not all species of Burkholderia are threatening to the human population, with some 
species being completely avirulent. Not only this, but some members, such as 




antagonistic activity against several plant pathogens, fixes nitrogen, and can aid in 
bioremediation (24).  
While the antimicrobial properties of the Burkholderia genus have been known 
for quite some time, including when it was still classified as Pseudomonas, the positive 
identification of the compounds uniquely produced by the various species is still 
relatively new and unexplored. An example of this is Burkholderia ambifaria 2.2N, a 
species that was undescribed until the year 2000 (25). While the antibiotic capabilities of 
the then-unknown bacterium were first documented then, it wasn’t until 2010 that the 
unique antifungal compounds were characterized (26). 
 Although the process of identifying antimicrobial products is no easy task, there 
have been major strides in four different types produced by Burkholderia: 
 
1.2.2 Xylocandins, cepacidines, occidiofungins and burkholdines 
Xylocandins, cepacidines, occidiofungins and burkholdines are among a class of 
novel lipopeptide and glycolipopeptide antifungal antibiotics produced by different 
Burkholderia species. Many of these have subvariants that are produced in smaller 
quantities, distinguished by slight differences in their peptide components or smaller 
modifications to the standard peptides present in the majority product. Structurally they 
are very similar in many respects, and their powerful antifungal activity is not new (27, 
28) (Figure 1.1). However, it was not until occidiofungin was discovered in 2009 that 
researchers began to explore in detail its structural properties as well as its mechanism of 




cepacidines (along with the burkholdines which were first described in 2012) share such 
a high degree of similarity that it would not be implausible to hypothesize that they share 
not only a similar means of production when compared  to occidiofungin, but also a 
similar, if not identical, method of killing its fungal target (29). 
Although peptidal in nature, occidiofungin does not involve the use of ribosomes 
or messenger RNA in its genesis. Instead, it relies on a hybrid system of a polyketide 
synthetase (PKS) coupled with a non-ribosomal peptide synthetase (NRPS), both of 
which rely on multi-domain enzymes to modify or elongate the growing peptide in some 
fashion. This nonstandard means of production often means that their products can result 
in modified amino acids different from the standard 20 amino acids most often 
encountered and are typically referred to as novel amino acids (NAA).  In the case of 
occidiofungin (of which there are two currently known variants, Occidiofungin A and 
Occidiofungin B), its production begins in with its nonribosomal peptide synthetase, 
however the hybrid system involves the polyketide synthetase’s products during key 
points of its production (30). 
The end result is a cyclized lipopeptide (or glycolipopeptide in the case of 
Occidiofungin B) with bactericidal activity against a broad spectrum of plant and animal 
pathogens, in particular yeast of the Candida genus (31, 32). Occidiofungin induces 
apoptosis by targeting actin, a family of proteins responsible for the formation of 







Iron acquisition is vital in Burkholderia species, whether in nutrient poor soil or 
in the iron-limited environment of the lungs.  Because of the highly conserved genome, 
up to four common siderophores can be observed being produced by the various species 
of the genus: ornibactin, pyochelin, cepabactin and cepaciachelin (33) (Figure 1.2). 
While the primary function of these compounds is the chelation and uptake of iron for 
use by the producing organism they have also been shown to have antimicrobial effects, 
as well as a play a role in the regulation of additional antibiotic capabilities. Likely due 
to the fact that their primary role is in iron-acquisition, the direct antimicrobial effect of 
Burkholderian siderophores is not explored in great detail. However, evidence has been 
shown that these play a role in growth inhibition of surrounding organisms, with 
bacteriostatic growth inhibition being attributed to iron-starvation of competing species. 
Burkholderia paludis MSh1T was shown to have antimicrobial activity when spotting 
dichloromethane extracts of culture supernatant but it is also a known producer of 
pyochelin, known primarily as a siderophore, which has bacteriostatic activity against 
four S. aureus strains and three E. faecalis strains. While not identified, the siderophore 
produced by Burkholderia cepacia XXVI was shown to inhibit the growth of 
Colletotrichum gloeosporioides, the fungal plant pathogen responsible for bitter rot in 
many tropical perennials (34, 35). Finally ornibactin, the most commonly produced 
siderophore amongst the different Burkholderia species, has shown to have bacteriostatic 
activity against the Gram-negative plant pathogen Erwinia amylovora. More 




been directly linked to bactericidal activity against the pathogenic species (36). 
Siderophore production and iron chelation has previously been shown to have a relation 
to the virulence of more pathogenic species of Burkholderia. This research suggests that 
attenuation of ornibactin production could open a new avenue to novel therapeutic 
approaches to these particular species. 
Of all the members of the Burkholderia genus, members of the Burkholderia 
cepacia complex contain the most published data examining their antimicrobial 
properties and products. As mentioned previously, these properties are not a new 
discovery. As a soil bacterium, Burkholderia are able to colonize the rhizosphere, 
providing growth promotion in plants and commercial crops (37). In addition to fixing 
nitrogen, use of BCC members and their antimicrobial products have possible 
applications in biocontrol and bioremediation, but need further research. An example 
being B. cepacia SCAUK0330, which showed strong bioactivity against numerous plant 




1.3 Burkholderia cenocepacia products 
Despite being one of the major colonizers of cystic fibrosis patients, 
Burkholderia cenocepacia has also been shown to produce compounds of interest. 
Among the strains tested, Burkholderia cenocepacia TAtl-371 has been examined the 
furthest. Siderophore production is evident, and antimicrobial activity of this particular 
strain has shown it to be active against Gram-negative species, including against other 
Burkholderia species. In addition, B. cenocepacia TAtl-371 also has strong activity 
against yeast and fungal species. Although success was had in isolating this activity, 
only one compound was successfully purified (“Compound one”), and it only had 
activity against one tested strain of Tatumella terrea (39). 
Another promising product comes from B. cenocepacia strain BC0425. This 
strain produces a tailocin, which is a phage tail-like bacteriocin. This tailocin was 
designated BceTMilo and proved to be quite effective against other members of the 
Burkholderia cepacia complex as well as 90% of the non-BCC Burkholderia species 
tested, opening up a possible avenue for new therapeutics against more pathogenic 
species that infect humans or crops (40). 
Finally, although not fully explored, Burkholderia cenocepacia P525 has also 
been studied for its antimicrobial capabilities, where a bacteriostatic oxidizer was found 







1.4 Burkholderia cepacia products 
The pathogenic Burkholderia cepacia also produces antimicrobial products. For 
example B. cepacia NB-1 has a broad spectrum activity. However, the organisms it is 
active against vary, with different pathogens appearing as sensitive in agar diffusion tests 
vs microtiter plates. Several strains have been recorded as producing the siderophore 
pyrrolnitrin including B. cepacia NB-1 (41). Some strains have also been shown to 
produce analogs of pyrrolnitrin as well. B. cepacia J82rif and J51rif, still identified by 
the antiquated Pseudomonas designation at the time of its publication, was reported to 
produce aminopyrrolnitrin and monochloroaminopyrrolnitrin (42). In addition to 
standard pyrrolnitrin, B. cepacia K87 also produces two pyrrolnitrin analogs: 3-chloro-4-
(3-chloro-2-nitrophenyl)-5-methoxy-3-pyrrolin-2-one (2) and 4-chloro-3-(3-chloro-2-
nitrophenyl)-5-methoxy-3-pyrrolin-2-one, however it was found that the antimicrobial 
activity of K87 is unstable when exposed to sunlight, and was readily metabolized in 
vivo (43). Finally, Burkholderia cepacia XXVI has also been reported to produce a 
siderophore with activity against the fungal pathogen Colletotrichum gloeosporioides; 
however the specific siderophore found in the study was not identified. 
The antifungal produced by B. cepacia CF-66 is the most characterized 
antimicrobial produced by the different strains of this particular species. The compound, 
designated as CF66I, was first reported in 2005 with its activity against Rhizoctonia 
solani (44, 45). Further studies expanding on this knowledge, as it exhibited activity 
against a wide range of plant pathogens, such as Fusarium and Colletotrichum. In 




temperature, even maintaining a measure of bioactivity when briefly exposed to 
temperatures as high as 160°C (46). It was later shown to be active against Candida 
albicans as well; however a definitive mechanism of action was not determined.  It was 
hypothesized that its activity was due to its effect on the assembly and integration of cell 
wall components, possibly by interrupting the interactions of hydrogen and hydrophobic 
bonds. When exploring its effects on Fusarium, at fungicidal concentrations CF66I was 
found to act on the cell membrane, which resulted in the cytoplasm leaking and 
ultimately leading to cell death. While it’s activity was notable against fungi and yeasts, 
it has no antibacterial activity (47). 
Alkyl-quinolones have also been reported as products of Burkholderia, with the 
entirety of genomovar I of B. cepacia producing two analogous 2-alkylquinolones with 
activity against Aspergillus niger. These two compounds were given the designation of 
Bc-255 and Bc-257, with Bc-255 having twice as much activity as Bc-257 (48) (Figure 
1.4). While this is a broadly produced antifungal, more detail was provided when B. 
cepacia Cs5’s antifungal activity was examined. Originally found in the rhizosphere of 
almond trees, three antifungals isolated from this strain were named Cs5-255, Cs5-257 
and Cs5-446, with Cs5-255 and Cs5-257 being found to be analogous (Figure 1.4). 
These antifungals were found to have activity against Aspergillus niger. Additional 
activity was found against Alternaria alternata,  Fusarium culmorum, F. graminearum, 
F. oxysporum and Rhizoctonia solani however this was found while testing activity with 
supernatant extracts of Cs5, so the product directly responsible for this activity is yet to 




The remaining products from B. cepacia have not been explored further since the 
1990’s. Although some were published while still designated under the genus 
Pseudomonas, they have been changed to Burkholderia to reflect their correct 
nomenclature here. In 1994, B. cepacia AF 2001 was found to produce two closely 
related compounds, cepacidine A1 and cepacidine A2. Once combined, the singular 
mixture was called cepacidine A, which has strong antifungal activity against several 
plant and human pathogens, which was diminished in the presence of serum. 
Furthermore, this particular compound exhibited no antibacterial activity (28, 50). The 
similarly named cepalycin I and II was isolated from B. cepacia JN106. Of the two, 
cepalycin I was the most active, having stronger antibiotic activity against S. cerevisiae 
and C. neoformans with a smaller measure of activity against C. albicans. Cepalycin II 
had reduced activity against  S. cerevisiae and C. neoformans, with no activity against 
Candida (51). Finally, an antifungal designated as AFC-BC11 was produced by 
Burkholderia pyrrocinia BC11 (formerly B. cepacia BC11), and was hypothesized to be 
a lipopeptide. This antifungal was active against R. solani, Pythium ultimum, 
Colletotrichum sp., Helmthosporium maydis, Botrytis cinerea, Fusarium sp., Rhizopus 
stolonifer, Rhodotorula glutinis, Sclerotium rolfsii, Scopulariopsis brevicaulis. 
Interestingly, although previously described cepadines are active against Candida, 







1.5 Burkholderia ambifaria products 
Although not many antimicrobials have been reported from Burkholderia 
ambifaria strains, burkholdines, which are structurally similar to occidiofungins, 
xylocandins, and cepacidines, have been isolated from one strain. From Burkholderia 
ambifaria 2.2N, Bk-1119, Bk-1213, Bk-1215, as well as Bk-1097 and Bk-1229 were all 
isolated (29). Similar to other antifungals produced by other Burkholderia species, these 
compounds exhibited strong antibiotic activity against S. cerevisiae, A. niger, and C. 
albicans (26). Among the more unique products of B. ambifaria is enacyloxin IIa and its 
stereoisomer iso-enacyloxin IIa, produced by strain AMMD. While this particular 
antibiotic is effective against multidrug resistant pathogens such as Acinetobacter 
baumannii, importantly it also has activity against its own genus, with examples 
including B. multivorans and B. dolosa. 
 
1.6 Burkholderia pseudomallei group products 
Burkholderia thailandensis was mentioned previously as being closely related to, 
yet lacking the virulence of B. pseudomallei. Although it is not the only member of the 
B. pseudomallei group that produces antimicrobials, it is likely the most studied. 
Currently it is known to produce bactobolin, a member of the polyketide-peptide family 
consisting of a C6-polyketide fused to a chlorinated hydroxy-valine residue. This 
particular compound was first found as a secondary metabolome in B. thailandensis 
strain E264, as it was noted a few years prior that production of this activity was under 




well, as B. thailandensis has been shown to also produce both bacteriocins and 
bacteriophages that were active against more virulent species of Burkholderia (55). 
 
1.7 Burkholderia xenovorans group products 
While the positive effects of Burkholderia has in agricultural applications is not 
new, often the source of the benefits remain unexplored. Within the Burkholderia 
xenovorans group there are four species which warrant further study: Burkholderia 
graminis, Burkholderia bryophila, Burkholderia megapolitana, and  Burkholderia 
phytofirmans PsJ have all been reported as having plant growth promotion, antifungal 
activity, or both yet have not been studied further (56-59).  
 
1.8 Other Burkholderia products 
Several different strains of Burkholderia gladioli have been shown to possess 
promising antimicrobial activity. In particular Burkholderia gladioli BCC0238, a strain 
which was originally isolated from a cystic fibrosis patient, produces gladiolin (Figure 
1.5).  This novel macrolide has been shown to inhibit RNA polymerase effectively in 
several Mycobacterium tuberculosis clinical isolates, while maintaining a low 
mammalian cytotoxicity (60). This is not the only antibiotic produced by BCC0238, as it 
has been shown to produce at an two-tailed lipopeptidiolide antibiotic known as 
icosalide A1 (Figure 1.3). Remarkably, this particular compound was originally isolated 
from a fungal culture before this bacterial origin was uncovered (61, 62). Among other 




most promising clinical products come from B. gladioli OR1, which produces at least 
five different products with bioactivity against Staphylococcus and Candida.  
Burkholderia gladioli pv. Cocovenenans has been shown to produce antifungal 
and antibacterial polyketides, but this activity was only when co-cultured with the 
fungus Rhizopus microspores (63). Finally, there appears to be agricultural applications 
for this particular species as well, as B. gladioli pv. Agaricicola and B. gladioli NGJ1 
exhibit broad-spectrum antifungal activity against the agricultural pathogens Rhizoctonia 
solani, Fusarium oxysporum, Magnaporthe oryzae, and Venturia inaequalis (64, 65). As 
of this writing these products have not been characterized. 
Burkholderia glumae also has similar possible applications in agriculture, as 
numerous strains exhibited activity against Rhizoctonia solani. Strain 411gr-6 produced 
a pigmented compound that also had strong antifungal activity against Colletotrichum 
orbiculare, however, none of the bioactive compounds in this particular study were 
further characterized, with a small exception (66). When investigating the antimicrobial 
pigmented compound of B. glumae 411gr-6 in a later study, two derivatives of the 
antibacterial phencomycin were uncovered as well (4-hydroxyphencomycin and 5,10-
dihydro-4,9-dihydroxyphencomycin methyl ester) (Figure 1.5) (67). Among other 
notable antibacterials produced by B. glumae strains designated as #3729 and #8657 
from the International Collection of Microorganisms from Plants were found to produce 
two products. Although one of these products was inactive once purified the second, an 
oxygenated pyrazole, displayed strong inhibitory activity against Erwinia amylovora, the 




determined it to be 3-[L-alanyl-L-homoserinyl-L-aspartyl-beta-carboxy]-4-hydroxy-5-




The purpose of this chapter is to provide an overview of the antimicrobial 
products that are currently known to be produced by the Burkholderia genus. While this 
Gram-negative soil bacterium does have a small number of pathogenic species, the 
majority of the genus is avirulent, with almost all member species capable of producing 
useful antimicrobial products that could potentially be a new means of therapeutics. This 
chapter also highlights the need for new treatment options, as the increasing prevalence 
of antibiotic-resistant pathogens, coupled with the declining rate of discovery for new 


















B. ambifaria  2.2N Burkholdines (Bk 1119, 1213 & 1215)†
B. contaminans  MS14 Occidiofungin†‡
B. ambifaria 2.2N Burkholdines (1097 & 1229)†
B. paludis  MSh1T Unknown
B. paludis  MSh1T Pyochelin
B. cepacia XXVI Unknown siderophore‡
B. cepacia  SCAUK0330 Unknown‡
B. cenocepacia  TAtl-371 Compound 1‡
B. cenocepacia  TAtl-371 Likely numerous unknowns‡
B. cenocepacia  TAtl-371 Lectin-like bacteriocin LlpA88‡
B. cenocepacia strain BC0425 Talocin (BceTMilo)
B. cepacia  NB-1 Pyrrolnitrin
B. cepacia  NB-1 Pyrrolnitrin
B. cepacia  J82rif and JSlrif Pyrrolnitrin, aminopyrrolnitrin, and monochloroaminopyrrolnitrin‡
B. cepacia  K87 Pyrrolnitrin‡
B. cepacia  germnovar I Bc-255 and Bc-257 (2-alkylquinolones)
B. cepacia  Cs5 Cs5-255 and Cs5-257 (alkylquinolones)
B. cepacia  Cs5 Cs5-446 (didecyl-phthalate)
B. cepacia  Cs5 Unknown
B. pyrrocinia  BC11 AFC-BC11
B. bryophila Unknown
B. megapolitana Unknown
B. phytofirmans  PsJN Unknown‡
B. gladioli  BCC0238 Gladiolin
B. gladiol i pv. cocovenenans  HKI 10521 (DSM 
11318; ATCC 33664)
Bongkrekic acid and Toxoflavin
B. gladioli  pv. agaricicola Unknown
B. gladioli NGJ1 Unknown‡
B. cepacia ATCC 39277 Xylocandin (A1 & A2)
B. cepacia  AF 2001 Cepacidine (A1 & A2)
B. cepacia  CF-66 CF66I‡
B. thailandensis  E264 Bactobolin
B. gladioli  Lv-StA (HKI0739) Icosalide A1
B. glumae  411gr-6 Phencomycin
B. cepacia ATCC 39277 Catacandin
B. cepacia  JN106 Cepalysin
†Indicates possible medical applications ‡Indicates possible agricultural applications

















S. cerevisiae, C. albicans, A. niger Yes 1119, 1213, 1215 Da 16
C. albicans  LL, C. albicans TE, C. albicans 66027, C. glabrata TE, C. glabrata  66032, C. parapsilosis 90018, C. tropicalis 66029, G. 
candidum , S. cerevisiae BY4741**
Yes 1200, 1216 Da
17
S. cerevisiae, C. albicans, A. niger Yes 1097, 1229 Da 21
E. faecalis  ATCC 29212, E. faecalis  ATCC 700802, S. aureus  ATCC 29213, S. aureus ATCC 700699, E. coli ATCC  25922 No N/A 23
E. faecalis  ATCC 29212, E. faecalis  ATCC 700802, E. faecalis  JH-22, S. aureus  ATCC 29213, S. aureus ATCC 700699, S. aureus  ATCC 
43300, S. aureus  ATCC 6538P
Yes 325 Da
23
Colletotrichum gloeosporioides No N/A 24
Exserohilum turcicum  SCAU3564, Helminthosporium maydis SCAU3321, Mycogone perniciosa  Magn SCAU3216, Rhizoctonia solani 
Ktihn SCAU3111, Alternaria alternata  (Fries) Keissler SCAU3471, Colletotrichum gloeosporioides  SCAU3725, Selerotium rolfsii  Sacc 
SCAU3025, Fusarium graminearum   Sehw.  SCAU3741, Fusarium oxysporum  SCAU3221
No N/A
27
Tatumella terrea  SHS2008 No 391 Da 28
Acinetobacter baumannii ATCC BAA-747, P. aeruginosa PAO1, S. aureus 55C1 No N/A 28
Only Bcc strains No N/A 28
Bcc strains, P. aeruginosa No N/A 29
Streptomyces antibioticus, S. violaceoruber, Paecilomyces variotii, Penicillium puberulum Yes 257 Da 30
Ustilago maydis, C. albicans, Hansenula anomala, Arthrobacter oxidans, Bacillus coagulans, B. lichenifernis, B. subtilis, B. 




Yes 257, 227, 223 Da
31
Rhizoctonia solani Yes N/A 32
A. niger Yes 255. 257 Da 37
A. niger Yes 255, 257 Da 38
A. niger Yes 446 Da 38
F. oxysporum, F. culmorum, F. graminearum, R. solani, A. niger, A. alternata No N/A 38
R. solani, Pythium ultimum, Colletotrichum sp., Helmthosporium maydis, Botrytis cinerea, Fusarium  sp., Rhizopus stolonifer, 
Rhodotorula glutinis, Sclerotium rolfsii, Scopulariopsis brevicaulis
Yes 733 Da
41, 58
V. dahliae, R. solani, C. albicans, X. campestris, P. ultimum No N/A 46
Verticillium dahliae, R. solani, Erwinia carotovora, S. aureus, Xanthomonas campestris, P. ultimum No N/A 46
Botrytis cinerea No N/A 47
Mycobacterium tuberculosis, Enterococcus faecium DSM25390, S. aureus DSM21979, C. albicans SC 5314 Yes 779 Da 49
R. microsporus
Yes 486.6, 193.1 Da
52
B. cinerea, A. flavus, A. niger, P. digitatum, P. expansum, S. sclerotiorum, P. cactorum No N/A 53
R. solani, Magnaporthe oryzae, Ventura inaequalis, Fusarium ocysporum No N/A 54
C. albicans, C. tropicalis, C. krusei, C. parakrusei, C. pseudotropicalis, C. guilliermondii, C. stellatoidea, C. glabrata, Trichophyton 
mentagrophytes,
No 1215, 1199 Da
14a
C. albicans, C. glabrata, Cryptococcus neoformans, S. cerevisiae, A. niger, Microsporium gypseum, M. canis, Epidermophyton 
floccosum, Trichophyton mentagrophyte, T. rubrum, F. oxysporum, Rhizopus stolonifer
Yes 1215, 1199 Da
15a, 39
C. albicans, R. solani, F. oxysporium, F. sambucinum, Rosellinia necatrix, A. flavus, A. niger, Cochliobolus carbonum, Botrytis 
cinerea, Mucor heimolis, Penicillium chrysogenum, Rhizopus oryzae, Cryptococcus neoformens, Pichia membranae, S. cerevisiae
No N/A
34, 35, 36
S. aureus, Streptococcus pyogenes Yes 383.2 Da 42, 43, 58
Bacillus thuringensis, Paenibacillus larvae, S. pyogenes Yes 712 Da 50, 51
Collectotrichum orbiculare Yes 299.06, 329 Da 55, 56
C. albicans, C. tropicalis, C. krusei, C. parakrusei, C. pseudotropicalis, C. guilliermondii, C. stellatoidea, C. glabrata Yes 344.4 Da 14a





Figure 1.1: Structures of hybrid PKS-NRPS antifungals occidiofungin, burkholdine and 
cepecidine. The structures of these cyclic peptides are highly similar, and the serine 



























Figure 1.4: 2-alkylquinolone antimicrobials produced by Burkholderia. Although Bc-
255 and Bc-257 have identical structures to Cs5-255 and Cs5-257, they are produced by 






Figure 1.5: Additional antimicrobials produced by Burkholderia species 
 
*Reprinted with permission from “The Siderophore Product Ornibactin Is Required for 
the Bactericidal Activity of Burkholderia contaminans MS14”  by Foxfire A, Deng P, 




2. SIDEROPHORE PRODUCT ORNIBACTIN IS REQUIRED FOR THE 
BACTERICIDAL ACTIVITY OF BURKHOLDERIA CONTAMINANS MS14* 
 
2.1 Overview 
Burkholderia contaminans MS14 was isolated from soil in Mississippi. When 
cultivated on nutrient broth–yeast extract (NBY) agar medium, the colonies exhibit 
bactericidal activity against a wide range of plant pathogenic bacteria. Only a 
bacteriostatic compound with siderophore activity was successfully purified, which was 
determined by nuclear magnetic resonance (NMR) to be ornibactin. The isolation of the 
bactericidal compound has not yet been achieved, thus, the exact nature of the 
bactericidal compound is still unknown. In an attempt to isolate bactericidal compound, 
an interesting relationship between the production of ornibactin and the bactericidal 
activity of MS14 was characterized. Transposon mutagenesis resulted in two strains that 
lost its bactericidal activity; an insertional mutation in a nonribosomal peptide synthetase 
(NRPS) gene for ornibactin biosynthesis and a luxR family transcriptional regulatory 
gene. Co-cultivation of these two mutant strains resulted in the restoration of the 
bactericidal activity. Ornibactin is produced by most Burkholderia species and further 
consideration for its role in regulating secondary metabolites in other species should be 




Identification of the antibacterial product from strain MS14 is not the key feature 
to this study, but rather the study demonstrates that ornibactin is involved in the 
bactericidal activity of MS14. Two mutants were isolated that had no bactericidal                            
activity. Mutations were in a luxR regulatory gene and an ornibactin biosynthesis gene.  
Growing these mutants in proximity to each other restored bactericidal activity in the 
ornibactin mutant strain. Ornibactin should be further evaluated for its role in regulating 
secondary metabolite biosynthesis in other Burkholderia species. 
 
2.2 Introduction 
The genus Burkholderia is composed of Gram-negative, rod-shaped, motile, 
environmental versatile and non-spore-forming bacteria that have been identified in 
many diverse ecological niches (68). Currently, 88 species have been recognized in the 
genus Burkholderia (69). The bacteria have the ability to use a large array of carbon 
sources to synthesize secondary metabolites (41, 70). Burkholderia cepacia complex 
(Bcc) is a group of Burkholderia species that include soil isolates and opportunistic 
bacteria which cause lung disease in immunocompromised individuals (71). The Bcc 
group composed of 9 different genomovars and at least 18 different species (72). 
Conversely, some strains of Burkholderia cepacia are related to the promotion of plant 
growth and are considered to be plant growth-promoting bacteria (PGPB). For example, 
B. cepacia strains could protect crops from the damping-off diseases caused by Pythium 
species and Rhizoctonia solani (70). Interests in the use of Burkholderia species or their 




have also been identified being produced by Burkholderia species, for example 
occidiofungin (73), pyrrolnitrin (41), pyoluteorin (74) and AFC-BC11 (52).  
Siderophores are small-molecule, ferric ion specific chelating agents secreted by 
bacteria and fungi growing under low iron stress. It scavenges iron from the environment 
and make it available to the microbial cell (75). Siderophores are bacteriostatic 
agents  that can inhibit pathogenic microorganism’s growth by depleting iron in the soil 
(76). Many siderophores are synthesized by NRPS and PKS pathways. NRPS and PKS 
are large multimodular enzymes, which are involved in natural product synthesis in 
many microorganisms (77). NRPS, involved in the biosynthesis of an oligopeptide, is 
grouped by active sites termed modules, in which each module is required for catalyzing 
one single cycle of product length elongation.  The order and number of the modules of a 
NRPS protein are mainly followed by the “collinearity rule” (78).   
Ornibactin is an NRPS product with siderophore activity. Ornibactin production 
in Burkholderia cepacia was shown to be critical for establishing an infection in a 
chronic respiratory infection murine model (79). Being able to sequester iron within the 
lung from iron-binding proteins, such as lactoferrin, is crucial for survival within the 
respiratory mucus (80, 81). There is a long understanding that the role of ornibactin in 
virulence is by providing a source of iron in iron restricted environments. Interestingly, 
the production of ornibactin appeared to also be important for bacterial adherence or 
colonization (79). In addition, the report shows that the absence of ornibactin production 
leads to a significant increase in the production of salicylic acid. This observation 




basis for these observations still remains to be explored. However, the study does 
suggest that ornibactin may have another biological role other than sequestering iron. 
In this study, we show that B. contaminans MS14 produces a bactericidal 
compound that has good activity toward Gram negative bacterial plant pathogens. The 
bacteriostatic compound ornibactin was isolated and confirmed by NMR. Two mutants 
that lack bactericidal activity were evaluated. One mutation was within a luxR regulator 
gene and the other mutation was within a nonribosomal peptide synthetase gene for 
ornibactin synthesis. It was shown that growing the ornibactin synthesis mutant in 
proximity to the luxR mutant restored MS14 bactericidal activity. These findings show 
that ornibactin is an important component for the production of the bactericidal 
secondary metabolite produced by B. contaminans MS14.   
 
2.3 Materials and methods 
2.3.1 Bacterial strains, plasmids and culture media  
Bacterial strains and plasmids used in this study are listed in Table 2.1. 
Escherichia coli strain TransforMaxTM EC100DTM pir+ (Epicentre Biotechnologies, 
Madison, WI, USA) was used for plasmid rescue cloning and cultured in Luria-Bertani 
(LB) medium at 37
o
C. Nutrient broth–yeast extract (NBY) agar medium (82) was used 
to culture Burkholderia strains and for plate bioassays of the antimicrobial activities 
evaluation.  Potato dextrose agar (PDA, Difco, Detroit, MI) was used for plate bioassays 
to evaluate antifungal activities. Antibiotics (Sigma Chemical Co., St. Louis, MO), if 






), kanamycin (100 mg ml
-1
 for Escherichia coli, 300 mg ml
-1
 for Burkholderia 
strains)  
 
2.3.2 Bioassay for antimicrobial activities  
B. contaminans MS14 and its mutants used in this study were evaluated for 
antibacterial activities against Erwinia amylovora 2029 and other pathogenic indicators 
using the NBY plate bioassays, similar to the protocol described by Scholz-Schroeder 
and colleagues (83). Briefly, MS14 and mutants were grown overnight in 5 ml of NBY 
liquid medium at 28
o
C. Then the bacterial cells were collected by centrifugation and 





). 5-µl aliquots of bacterial suspension were inoculated onto the center 
of NBY plates. The plates were then incubated for 3 days at 28°C. Afterwards, the NBY 
plates were oversprayed with suspension of indicator pathogenic bacteria (OD420=0.3) 
and PDA plates were oversprayed with the indicator fungus (OD420=0.3), respectively. 
Inhibition zones were measured from the margins of bacterial colonies after 24 hours, 
with the size of the zone compared between B. contaminans MS14 and its mutants. To 
differentiate bactericidal activity from bacteriostatic activity, agar plugs (1 x 1 mm each) 
within the zones of inhibition to the indicator bacterium Erwinia amylovora 2029 were 
removed and grown on culture media. Bactericidal activity was indicated by no growth 
of the indictor bacterium. A minimum inhibitory assay of purified antimicrobial 






2.3.3 Random mutagenesis  
The EZ-Tn5 <R6Kcori/KAN-2>Tnp Transposome kit (Epicentre 
Biotechnologies, Madison, WI) was used to characterize the genes dedicated to 
antibacterial activity of B. contaminans MS14. B. contaminans MS14 are able to aquire 
kanamycin resistance on NBY plates through an EZ::TN transposon insertion into the 
genome, and mutants are able to be selected on the NBY plates supplemented with 300 
g ml
-1 
kanamycin. The mutants that exhibited reduced or no antibacterial activity 
against Erwinia amylovora were isolated. 16S rRNA and recA genes were cloned and 
sequenced, confirming that the resulting mutants were derivatives of strain B. 
contaminans MS14. Plasmid rescue cloning was performed according to the 
transposome kit instructions to generate plasmids pPD357 and pPD577 (Table 2.1). A 
portion of the Tn5 transposon sequence was amplified by PCR with the primers R6kF1 
(5’- GGGTAGCCAGCAGCATCCT-3’) and R6kR1 (5’- 
CATGATCGTGCTCCTGTCGTT-3’) to confirm that the rescue plasmid contained the 
transposon sequence. The positive rescue clones were sequenced for further analysis. 
Sequence analysis was accomplished using the Lasergene Cloning suite version 12 
(DNASTAR, Inc., Madison, WI). Genes were searched against the B. contaminans 
MS14 reference genome (84). BLASTn comparison of genomes was visualized by 






2.3.4 Analysis and isolation of the siderophore product  
The wild-type strain MS14 was grown on modified NBY (487 mL distilled 
water, 2.5 g peptone, 1.5 g Todd Hewitt, 1.0 g Yeast Extract, 1.0 g K2HPO4 (anhydrous), 
0.25 g KH2PO4, and 1.5% agar; 12.5 mL of 20% glucose and 0.5 mL of 1M MgSO4 was 
added after autoclaving) agar plates overnight at 28°C. Colonies from the overnight 
NBY agar plate were stabbed into 500 mL of modified NBY soft agar (NBY with only 
0.75 % agar). The inoculum in soft agar was placed at 28 °C for 4 days, and immediately 
frozen at -80°C. The media was then thawed in a 55°C water bath for 1 hour. The 
inoculum was then placed in 250 mL centrifuge bottles and centrifuged at 20,000 g for 
30 minutes. The collected supernatant was pooled, mixed with 1 gram of poly-aromatic 
absorbance resin Diaion HP-20 and shaken for one hour. The resin was allowed to settle 
before decanting the supernatant and was resuspended in 10 mL of 50% 
acetonitrile:water. The extract was dried by lyophilization and resuspended in 1mL of 
35% acetonitrile:water. The extracts were tested for siderophore and antibacterial 
activity by spotting 10 µL of the extract on a Chrome azurol S (CAS) plates or on an 
NBY plate overlaid with Erwinia amylovora 2029. RP-HPLC was done using a 4.6 × 
250 mm C18 column (Grace-Vydac, catalog 201TP54) on a Bio-Rad BioLogic F10 Duo 
Flow with Quad Tec UV-Vis Detector system. Fractions were separated using a thirty 
minute gradient of 90:10 water:acetonitrile:0.1% trifluoroacetic acid to 20:80  






2.3.5 Structural determination by NMR of the siderophore product 
A 2 mM sample of the purified bacteriostatic compound was prepared in (50:50) 
acetonitrile-d3 (Cambridge Isotopes):H2O. The NMR data were collected on a Bruker 
AVANCE III HD 600 MHz spectrometer and a Bruker AVANCE III HD 850 MHz 
spectrometer, using TCI cryoprobes on each spectrometer. The 
1
H resonances were 
assigned according to standard methods (86) using COSY, TOCSY, NOESY and 
13
C-
HSQC experiments.  NMR experiments were collected at 10°C. The carrier frequency 
was centered on the water resonance, which was suppressed minimally using standard 
presaturation methods. A 2.0 s relaxation delay was used between scans. The TOCSY 
experiment was acquired with a 60 ms mixing time using the Bruker DIPSI-2 spinlock 
sequence. The NOESY experiment was acquired with 400 ms mixing time. The 
parameters for collecting the HSQC spectrum were optimized to observe aliphatic and 
aromatic CH groups. The spectral sweep width for the TOCSY and NOESY was 11.35 
ppm in both dimensions. The spectral sweep widths for HSQC were 11.35 ppm in the 
proton dimensions and 0 and 85 ppm for the carbon dimension. All 2D data were 
collected with 2048 complex points in the acquisition dimension and 256 complex points 
for the indirect dimensions, except for the HSQC which was collected with 2048 and 
128 complex points in the direct and indirect dimension, respectively. Phase sensitive 
indirect detection for NOESY, TOCSY, and COSY experiments was achieved using the 
standard Bruker pulse sequences. 
1
H chemical shifts were referenced to the residual 
water peak (3.33 ppm). Data were processed with nmrPipe (87) by first removing the 




squared sinebell function with 45 or 60 degree shifts (for the 
1
H dimension of HSQC), 
zerofilling once, Fourier transformation, and baseline correction. Data were analyzed 
with the interactive computer program NMRView (88).  
 
2.3.6 Mass spectrometry of the siderophore product 
The mass of the purified bacteriostatic product was confirmed on a Shimadzu 
matrix-assisted laser desorption ionization mass spectrometer (MALDI-MS) in both the 
linear and reflectron modes. The isolated compound was analyzed by electrospray mass 
spectrometry (ESI-MS) using a Micromass Q-TOF II mass spectrometer. The compound 
was dissolved in 50/50 acetonitrile/water (v/v) with 0.1% formic acid and injected into a 
1 μL/min flow of the same solvent using a Harvard syringe pump. The flow was sprayed 
using the nano-LC interface. Tandem MS (MS/MS) was performed with singly charged 
ions using standard collision energy (34 V) and higher collision energy (50 V). 
 
2.3.7 Plasmid construction for LuxR gene complementation 
The intact LuxR gene was amplified using the primer pair LuxRF (5’-
CTGAGGATCC ATTCAAACTAAACGAACGGGG-3’) and LuxRR (5’-
GACGAAGCTTTGGCTCAGCGC GTTTC-3’), in which the restriction endonuclease 
cutting sites BamHI and HindIII were added. The resulting PCR product containing the 
intact wild-type LuxR gene were digested using the respective enzymes, then cloned into 
the expression vector pMLS7 to generate plasmid pDP357-2, as previously described 




cells to recover the wild-type characteristics. An empty vector was used as negative 
control. Single colonies were picked from NBY plates supplemented with trimethoprim 
(100 g ml
-1
) and kanamycin (300 g ml
-1
). The plasmid was successfully extracted 
from the colonies. Sequencing results confirmed the existence of the resultant plasmid 




2.4.1 Antibacterial activity of MS14 
Burkholderia contaminans MS14 has previously been shown to produce a potent 
antifungal named occidiofungin (90). In this study, zone of inhibition plate assays of 
strain MS14 grown on nutrient broth–yeast extract demonstrated significant bactericidal 
activity against a broad array of plant bacterial pathogens (Figure 2.1 and Table 2.2). 
Cultivation of agar plugs within the zones of inhibition from the indictor bacterium 
Erwinia amylovora did not yield in any viable colonies, supporting the classification of 
the MS14 antibacterial product as a bactericidal compound. Xanthomonas citri pv. 
malvacearum, one of a most destructive pathogen on cotton (91), is best inhibited by 
strain MS14 with a radius of 39 mm clear non-growing zone formed on the plate. 
Pectobacterium carotovorum WSCH1, which is the pathogen of bacterial soft rot on 
potato and other vegetables (92), Ralstonia solanacearum, which causes bacterial wilt of 
tomato and potato (93), were also significantly inhibited by strain MS14.  The fire blight 




pathogen Burkholderia glumae (95) were also highly sensitive to MS14 with a inhibition 
zone radius of 23 mm and 22 mm, respectively. Plates assays revealed that strain MS14 
could significantly inhibit the gram-positive bacteria Clavibacter michiganensis subsp. 
michiganensis, the pathogen of a major tomato disease, tomato wilt and canker (96). 
However, another Gram-positive bacteria Bacillus megaterium, was not very sensitive to 
the growth of strain MS14 compared to other pathogenic bacteria tested. Overall the data 
indicate that the cell metabolites of strain MS14 have possible application as potent 
broad spectrum antibacterial agent against plant pathogens. Mutagenesis analysis of 
MS14 generated antibacterial-defective mutants MS14MT357 and MS14MT577 
retained a similar antifungal pattern compared to the wild strain (Figure 2.6). The data 
indicate that the antibacterial mechanism is independent from the antifungal 
occidiofungin production. 
 
2.4.2 Identification of genes involved in production of the antibacterial product 
Mutants of strain MS14 created by EZ-Tn5 transposon insertion were obtained 
and were tested for antibacterial activity against our indicator strain of Erwinia 
amylovora. Two mutants that lost activity in the overlay assay were named MS14MT357 
and MS14MT577. Plasmid rescue method obtained plasmids (pDP357 and pDP577) 
from the genomes of the mutants respectively. Plasmids details are shown in Table 1.1. 
BLAST analysis using the DNA sequence generated from the plasmids pDP357 rescued 
from the mutant MS14MT357 against the MS14 genome showed that the disrupted gene 




Sequence analysis of pDP577 revealed that the disrupted gene in mutant MS14MT577 is 
the gene locus NL30_RS14890, which is 9,662 bp in size (Figure 2.8) and encode a 
3,219-aa peptide. The deduced peptide of NL30_RS14890 shares a 93% identity with 
the orbI gene in B. cenocepacia J2315, which is one of the two NRPS genes for 
siderophore ornibactin biosynthesis (97). Given the size of the gene product in the 
MS14MT577 mutant, complementation cannot be achieved. Furthermore, the possibility 
of any polar effects would be on downstream genes for the biosynthesis of an ornibactin 
related compound. 
 
2.4.3 Complementation of the mutated LuxR type gene 
The intact LuxR family transcriptional regulator gene was cloned into the 
Burkholderia expression vector pMLS7 using the primer pair LuxRF (5’-
CTGAGGATCCATTCAAACTAAACGAACGGGG-3’) and LuxRR (5’-
GACGAAGCTTTGGCTCAGCGCGTTTC-3’) with BamHI and HindIII enzyme 
digesting sequence added, respectively.  The cloned LuxR genes were regulated by the 
S7 ribosomal protein promoter (98). The generated plasmid pDP357-2 was transformed 
into the mutant MS14MT357 to be expressed constitutively. Plate bioassays revealed 
that the antibacterial activities of these mutants against Erwinia amylovora had fully 
been restored to the wild-type level as compared with the strain MS14 (Figure 2.9). 
Considering EZ-Tn5 transposome was previously reported to have no polar effects 
leading to the inactivation of downstream genes (99) and LuxR gene complementation 




unlikely to be effected by the insertional mutagenesis. The result showed that the LuxR 
family transcriptional regulator is essential for the observed bactericidal activity in strain 
MS14.   
 
2.4.4 Isolation and characterization of products from MS14MT357 and MS14MT577 
Wild-type strain MS14 and mutant strains MS14MT357 and MS14MT577 were 
cultured and extracted following an identical procedure. Extracts were run on a RP-
HPLC column to determine differences within the isolated products. The wild-type 
MS14 and MS14MT357 had a comparable peak at the retention time of 18 minutes 
eluting in 64:36 water:acetonitrile (Figure 2.2). The mutant strain MS14MT577 did not 
produce a similar product at this retention time. In a minimum inhibitory assay, the 
fraction at 18 minutes was the only product that exhibited any inhibitory activity against 
E. amylovora, but this activity was clearly not bactericidal. The initial Diaion HP-20 
extracts had bactericidal activity in a zone of inhibition plate assay, but the bactericidal 
activity was not recovered from any RP-HPLC fraction. The isolation of the bactericidal 
compound has not yet been achieved.   
The bacteriostatic product was isolated from wild-type MS14 and the structure 
was characterized by COSY, TOCSY, NOESY, and HSQC NMR (Figure 2.10, Figure 
2.11, Figure 2.12, and  Figure 2.13) and mass spectrometry. NMR analysis revealed that 
the purified product contained TOCSY spin systems for a 3-hydroxyoctanoic acid 
(HOA), ornithine, aspartic acid (Asp), serine (Ser), and putrescine (Put) (Figure 2.3 and 




NOESY experiment confirming the assigned position of each residue within the 
structure. NOEs were observed between the Orn(Nδ-OH)1λ to Asp(β-OH)2NH, Orn(Nδ-
OH)1α to Asp(β-OH)2NH, Asp(β-OH)2α to Ser3NH, Ser3α to Orn(Nδ-OH)4NH, 
Orn(Nδ-OH)4δ to Formyl, Orn(Nδ-OH)4α to PutNH, and Ser3α to Put NH3+ (Figure 
2.14 and Figure 2.15). The isolated product was structurally determined to be ornibactin-
F with a mass of 737 Da. In addition, a chrome azurol S (CAS) plate assay was used to 
demonstrate that the isolated product had siderophore activity (Figure 2.16). The 
observed lack of the product in the MS14MT357 strain is to be expected given that the 
mutation is within the biosynthesis pathway for ornibactin.   
 
2.4.5 Co-culture of MS14MT357 and MS14MT577 restores bactericidal activity 
The isolated ornibactin-f product does not account for the bactericidal activity 
observed in the wild-type strain. This is also supported by the lack of bactericidal 
activity in the MS14MT357 strain that is capable of producing the same ornibactin 
product as wild-type MS14. Therefore, ornibactin is not directly responsible for the 
observed bactericidal activity. The relationship between ornibactin production and the 
LuxR family transcriptional regulator for the synthesis of the bactericidal compound was 
further evaluated using a plate overlay assay (Figure 2.4). The mutant strains 
MS14MT357 and MS14MT577 were spotted on a plate in the shape of a "V", in which 
the colonies at the bottom are comprised of a mixed culture. Siderophore bacteriostatic 
activity is observed around each colony of the MS14MT357 strain along the right side of 




the left side of the “V”. The bactericidal activity, which is observed by the clear zone of 
inhibition at the bottom of the “V”, is only present when the MS14MT357 and 
MS14MT577 mutants are grown in close proximity. The synthesis of both the LuxR 
family transcriptional regulator and ornibactin is required to produce the bactericidal 
compound. To further test this observation, the bactericidal and siderophore activity was 
tested with elevated concentrations of ferric iron. Increasing concentration of ferric iron 
has been shown to regulate the synthesis of ornibactin (100). If ornibactin is directly 
involved in the regulation of the bactericidal product, bactericidal activity should absent 
at the same ferric iron concentration that inhibits ornibactin biosynthesis. A concomitant 
loss of siderophore activity and bactericidal activity was observed in Diaion HP-20 
extracts with increasing concentration of available ferric iron (Figure 2.17A&B). The 
loss of siderophore and bactericidal activity corresponded to the observed loss of the 
ornibactin product by RP-HPLC (Figure 2.17C). The data supports the observation that 
ornibactin is indirectly required for bactericidal activity of MS14. One possibility is that 
an ornibactin byproduct is responsible for the observed bactericidal activity. This would 
suggest that luxR gene NL30_RS14390 product is involved in the regulation of a product 
that modifies ornibactin. This scenario is unlikely, given that this product should 
presumably be isolated by the same extraction method used to isolate ornibactin. It is 
more likely that ornibactin has a regulatory role in MS14 and that it promotes the 
synthesis of a bactericidal secondary product. This is supported by the observation that 
bactericidal activity is only restored in the mutant deficient in ornibactin production and 




2.4.6 Genetic architecture of ornibactin biosynthesis locus among Burkholderia species 
Given the fact the relationship between the production of ornibactin and Bcc 
virulence remains unclear (101), the ornibactin biosynthesis locus is compared within 
Burkholderia species (Figure 2.5).  B. cenocepacia is selected as the reference given the 
ornibactin biosynthesis locus is best described in strain J2315 (97, 102). Using this 
reference the ornibactin loci were identified from thirteen Burkholderia species, which 
includes the pathogenic species B. multivorans ATCC 17616, B. mallei ATCC 23344, B. 
thailandensis E264, B. oklahomensis EO147, B. pseudomallei 1026b and B. 
pseudomallei K96243  (103-106), the PGPB B. lata 383, B. ambifaria AMMD and B. 
phytofirmans PsJN (107-109), soil isolates B. cepacia GG4, B. vietnamiensis G4, B. 
phymatum STM815 and B. xenovorans LB400 (110-112). The comparison of ornibactin 
loci showed a high degree of conservation of the orbl, orbJ, orbE and pvdA genes, which 
are responsible for ornibactin biosynthesis and ornibactin export across cytoplasmic 
membrane. MS14 NRPS gene NL30_RS14885 and NL30_RS14890 share a 90% 
nucleotide identity with the orbJ and orbI genes in B. cenocepacia J2315 and deduced 
peptides share 93% and identity with those in J2315. Conversely, the genes from orbS to 
orbB and from orbA to orbL, which involved in ornibactin biosynthesis initiation, 
regulation, transportation and modification, show significant diversity within the studied 
Burkholderia genome. We also analyzed the plant pathogenic B. glumae BGR1 and B. 
gladioli BSR3 (113, 114), however the ornibactin biosynthesis locus is not identified 






The findings from this study demonstrate that MS14 has antibacterial activities 
against a wide range of plant pathogenic bacteria that includes Erwinia amylovora, 
Xanthomonas citri pv. malvacearum, and Clavibacter michiganensis subsp. 
michiganensis. Random mutagenesis studies resulted in the identification of two mutants 
in MS14 that had a loss in antibacterial production. Both of these mutations occur within 
regions that are not directly involved with the biosynthesis of the bactericidal product. 
Bactericidal activity could be restored by growing the ornibactin NRPS mutant and the 
LuxR family transcriptional regulatory mutant in proximity, suggesting that ornibactin 
production is essential for the production of the antibacterial compound.  We have also 
showed a significant amount of diversity within Burkholderia species for the regions 
within ornibactin biosynthesis that would influence regulation and transport. Given the 
genomic diversity of these regions, ornibactin presumably has evolved to have additional 
functional roles aside from iron sequestration and iron uptake.  
The determined structure of the isolated siderophore from our analysis is the 
same as has been previously reported for ornibactin-F (115). The mass for this product is 
also similar to the reported mass for ornibactin-F, i.e. 737 Da  (115). Ornibactin (100) is 
a tetrapeptide siderophore that was first reported being produced by Pseudomonas (116) 
and then by several B. cenocepacia strains (100, 117). The ornibactin gene cluster 
contains two core NRPS genes (97), each of which is comprised of an amino acid 
adenylation domain and a condensation domain. The two domains are core components 




microorganisms (118). These domains are also conserved among the Burkholderia 
species that were compared (Figure 2.5).  
A LuxR family transcriptional regulator and the synthesis of ornibactin are 
essential for the production of a bactericidal compound in B. contaminans MS14 under 
the tested culture conditions. A concentration of ≤15 µM ferric iron was enough to 
suppress ornibactin biosynthesis by members of the Burkholderia cepacia complex. 
Ornibactin production was shown to be suppressed with 100 µM ferric iron with a 
concomitant loss of bactericidal activity (Figure 2.17). Comparison of the ornibactin 
gene cluster with fourteen previously sequenced Burkholderia species, including plant-
growth-promoting strains and mammalian pathogenic strain, indicated that the ornibactin 
biosynthesis gene cluster commonly exists among other Burkholderia species. The 
diversity within the regulatory and transport regions within the gene cluster for 
ornibactin biosynthesis supports additional regulatory roles for the compound within 
Burkholderia species. In the case of MS14, it does have a clear role for promoting the 
antibacterial activity of the strain. Given the requirement of ornibactin for the production 
of the bactericidal compound in MS14, ornibactin may also be crucial for the synthesis 
of other secondary metabolites or possible virulence factors within other bacterial 
systems. It is becoming clearer that ornibactin has a larger role than iron sequestration 
and uptake within some bacterial systems and that a better understanding of these 
alternative activities could possibly promote the isolation of novel secondary metabolites 






This study uncovered that ornibactin, primarily thought of as a siderophore, has a 
secondary function beyond iron uptake for a B. contaminans MS14 bacterium. 
Ornibactin plays a key role in the regulatory pathway of an antibacterial secondary 
metabolite, with its absence leading to a complete loss of production of this metabolite. 
This is an exciting discovery as it could potentially be applied to more virulent strains of 
Burkholderia, This could lead to a new means of therapeutics if it is explored further if 


















Table 2.1: Bacterial strains and plasmids 
 
Strains or plasmids Relevant characteristics Sources 
Escherichia coli 
    Ec100D 
F
-
 mcrA Δ(mrr-hsdRMS-mcrBC) φ80dlacZΔM15 
ΔlacX74 recA1 endA1 araD139 Δ(ara, leu)7697 galU 








MS14 Wild-type strain  
MS14MT357 LuxR regulator gene::Tn5 derivative of MS14; Km
r
 This study 
MS14MT577 NRPS gene::Tn5 derivative of MS14; Km
r
 This study 
Plasmid 
pDP357 

















pMLS7 carrying 828bp BamHI and HindIII fragment 









Table 2.2: Antibacterial activities of Burkholderia contaminans MS14 
Indicator Pathogenic Bacteria 
Inhibition Zone Radius (mm) 
MS14 MT357 MT577 
Xanthomonas citri pv. malvacearum MSCT1 36±1.66 0 0 
Pectobacterium carotovorum subsp. carotovora EC101 33±0.86 0 1±0.5 
Ralstonia solanacearum 102 31±0.08 0 0 
Pseudomonas syringae pv. syringae B301D 29±1.00 0 0 
Erwinia amylovora 2029 23±0.85 0 0 
Burkholderia glumae 291 22±0.08 4±1.55 5±1.30 
Escherichia coli JM109 22±0.77 0 0 
Clavibacter michiganensis subsp. michiganensis 1-07 17±0.07 0 0 















Table 2.3: Chemical shift values for the siderophore product ornibactin 
 
Residue 1H 13C Residue 1H 13C 
HOA-C-2 2.67/2.47 42.56 Ser3-NH 8.05  
HOA-C-3 3.98 71.42 Ser3-C 4.33 - 
HOA-C-4 1.45/1.36 39.91 Ser3-C 3.82/3.75 64.13 
HOA-C-5 1.25 34.58 Orn4(N-OH)-
NH3+ 
8.14/8.04  
HOA-C-6 1.25 28.13 Orn4(N-OH)-C 4.20/4.18 52.74 









- - Orn4(N-OH)-C 3.48/3.17 53.14 
Orn1(N-OH)-C 4.08 56.09 N-formyl   
Orn1(N-OH)-C 1.55 24.33 Put-NH 7.77  
Orn1(N-OH)-C 1.77 31.25 Put-C-1 3.14 41.79 
Orn1(N-OH)-C 3.74/3.47 50.23 Put-C-2 1.47 28.65 
Asp2(-OH)-NH 8.57 - Put-C-3 1.53 27.36 
Asp2(-OH)-C 4.89 59.70                               Put-C-4 2.88 42.56 







Figure 2.1: Antibacterial activity of Burkholderia contaminans MS14 against (1) 
Xanthomonas citri pv. malvacearum MSCT1, (2) Pectobacterium carotovorum WSCH1, 
(3) Ralstonia solanacearum, (4) Pseudomonas syringae pv. syringae B301D, (5) 
Erwinia amylovora 2029, (6) Burkholderia glumae 291, (7) Escherichia coli, and (8) 
Clavibacter michiganensis subsp. michiganensis Lu-01. 5-µl aliquots of bacterial 
suspension (OD420=0.3) were inoculated onto the center of NBY plates. After the plates 
were incubated for 3 days at 28°C, the NBY plates were oversprayed with suspension of 
indicator pathogenic bacteria (OD420=0.3). Inhibition zones were measured from the 





Figure 2.2: RP-HPLC chromatograms. Overlay of the chromatograms of the final 
purification step of the wild-type MS14 fraction, MS14MT357, and MS14MT577 at 220 








Figure 2.3: TOCSY spin system correlations of the siderophore product. Fingerprint 
region (NH correlations), alpha to side chain correlations and side chain correlations are 







Figure 2.4: Bioassay for antibacterial activity. The two mutant strains MS14MT357 and 
MS14MT577 were spotted and grown overnight, heat killed, and overlayed with 
indicator strain E. amylovora. The bacteriostatic activity of ornibactin production in the 
MS14MT357 strain is visible by the observed growth reduction of the indicator strain. 









Figure 2.5: Ornibactin biosynthesis locus genetics of Burkholderia species. Image 











Figure 2.6: Antibacterial activity of Burkholderia contaminans strain MS14 against 
Erwinia amylovora was lost in MS14MT357 and MS14MT577 (A). Antifungal activity 

















Figure 2.7: A 10-Kb genomic region of Burkholderia contaminans strain MS14 with the 
















Figure 2.8: A 34-Kb genomic region of the Burkholderia contaminans strain MS14 with 
















Figure 2.9: Constitutive expression of the LuxR homolog gene could restore the 











































Figure 2.15: Covalent structure of ornibactin-F.  The position of each amino acid is 
labeled in the tetrapeptide. The location of the 3-hydroxyoctanoic acid (HOA), 












Figure 2.16: Chrome azurol S (CAS) plate assay. The wild-type MS14 and 
MS14MT357 strains have a clear zone of siderophore activity, while the MS14MT577 








Figure 2.17: Bioactivity with supplemented ferric iron. A. Antibacterial activity of 
Diaion HP-20 extracts against Erwinia amylovora with cultures grown in 15(1), 30(2), 
50(3), and 100(4) µM ferric iron. B. Chrome azurol S (CAS) plate assay of Diaion HP-
20 extracts with cultures grown in 15(1), 30(2), 50(3), and 100(4) µM ferric iron. C. RP-
HPLC chromatograms of Diaion HP-20 extracts of cultures grown in 15(1), 30(2), 50(3), 
and 100(4) µM ferric iron. No siderophore or bactericidal activity is observed in cultures 





3. BIOPHYSICAL CHARACTERIZATION OF THE BACTERICIDAL 
COMPOUND PRODUCED BY B. CONTAMINANS MS14  
 
3.1 Overview 
There is an urgent need for the discovery of novel antibiotics for the treatment 
and prevention of infectious diseases in humans, animals, and plants. Burkholderia 
contaminans MS14 is known for its ability to produce a potent antifungal compound 
named occidiofungin. This bacterium has previously been shown to produce several 
compounds that have bactericidal properties; it also produces a bacteriostatic agent, 
ornibactin-F. Ornibactin-F is also involved in the bactericidal properties of this strain. 
This bactericidal activity was first observed in deferred antagonism assays while 
culturing MS14 in nutrient-rich media. The bactericidal activity was more selective 
toward Gram-negative organisms vs Gram-positive, and with no activity against fungi. 
In this report, we cover the work regarding the isolation and characterization of an 
unknown, novel antibacterial compound. This compound, while unknown and unnamed, 
is likely a novel antibiotic given similarity to a previously described polyketide 
biosynthetic gene cluster for malleilactone and the biophysical and bioactivity 






The genus Burkholderia is composed of Gram-negative, rod-shaped, motile, 
environmentally versatile and non-spore-forming bacteria that have been identified in 
many diverse ecological niches (68). Currently, 88 species have been recognized in the 
genus Burkholderia (69). The bacteria have the ability to use a large array of carbon 
sources for various metabolic purposes, including synthesizing secondary metabolites 
(41, 70). Burkholderia cepacia complex (BCC) is a group of Burkholderia species that 
include soil isolates and opportunistic bacteria which may cause lung disease in 
immunocompromised individuals (71). Alternatively, some strains of the BCC are 
related to the promotion of plant growth and are considered to be plant growth-
promoting bacteria. One member of the BCC with plant-growth promoting and 
antimicrobial activity is Burkholderia contaminans strain MS14. Of the members of the 
both Burkholderia genus and the BCC, B. contaminans MS14 is the most studied strain 
describing many facets of the antimicrobial agents produced.  The confirmed 
antimicrobial secondary metabolites that are produced by MS14 are the antifungal 
occidiofungin (73) and the siderophore ornibactin (36), which has bacteriostatic 
bioactivity in addition to its normal role in iron acquisition. There is also evidence that 
an additional antibacterial metabolite is produced, and is regulated by the presence of 
ornibactin. This additional product can be observed in deferred antagonism assays, with 
lethal activity against many Gram-negative and Gram-positive indicator bacteria (Figure 
3.1) (36). Ornibactin appears to be involved in the regulation of the production of the 




capable of producing the bactericidal compound when grown in the presence of 
supplemented ornibactin (36). With the activites of occidiofungin and ornibactin already 
known, it was hypothesized that the new antibacterial compound was a polyketide. 
Polyketides are a diverse group of natural compounds comprised of alternating 
carbonyl and methylene groups. While a number mycotoxins produced by fungi fall into 
the category of polyketides (119), there are also many that have been found to have 
beneficial antibacterial activity. Polyketides have been organized into different classes, 
primarily based on their structure and the manner in which they are synthesized. Type I 
polyketide synthetases (PKS) are linearly arranged and covalently fused catalytic 
domains within large multifunctional enzymes. These are produced by both bacteria and 
fungi. Type II polyketides include a dissociable complex of monofunctional enzymes, 
and are exclusively produced by bacteria. Type II polyketides include one of the more 
well-known group of broad-spectrum antibiotics, tetracyclines. Finally, Type III 
polyketides are commonly associated with chalcones, an organic compound frequently 
employed as a defense mechanism in plants. As one might infer, Type III polyketides are 
most often produced by plants, however there are some produced by bacteria and fungi 
(120). Polyketides make up a number of well-documented and effective antimicrobials: 
in addition to the previously mentioned tetracyclines, the antibacterials erythromycin and 
azithromycin, as well as the antiparasitic ivermectin, are just some of the examples of 
polyketide antibiotics commonly in use today. An example of a polyketide produced by 
Burkholderia would be malleilactone. The enzymes that make malleilactone are encoded 




species. While having minor antimicrobial activity on its own, it is cytotoxic to 
mammalian cells, as well as being a virulence factor for B. pseudomallei, the causative 
agent of melioidosis (121, 122).  Because of the presence of bactericidal activity in B. 
contaminans MS14, separate from the bioactivity produced by occidiofungin and 
ornibactin, experiments were performed with the goal of isolating the bactericidal 
product for further characterization.  
While there are numerous extraction methods available, there are a number of 
approaches that are particularly helpful when attempting to isolate proteinaceous 
compounds such as the antimicrobial compounds frequently isolated in the Smith Lab 
(123). When considering different methods of chromatography, size-exclusion, ion-
exchange and reverse-phase are applicable for this function. As the name implies, size-
exclusion chromatography separates compounds based on size. This separation is 
achieved through the use of a resin or beads in the stationary phase that contains many 
pores or channels. These pores are small enough to where smaller molecules are able to 
easily enter and thus will have to travel through these pores as they make their way to 
the bottom of the column, increasing their retention time. Because larger molecules are 
unable to fit through these pores, they pass by, needing only to travel around the larger 
beads that comprise the resin. This method allows for larger compounds to elute more 
rapidly, leading to separation based on size (123). Ion-exchange chromatography 
behaves in a similar principal to separation based on polarity, but rather than the 
stationary phase binding to the compound through hydrophilic or hydrophobic 




which will then bind to the compound of interest. Compounds in the mobile phase that 
are unable or only capable of weak interactions with the stationary phase are easily 
washed and eluted off while the compounds with strong electrostatic interaction remain 
on the column. Elution of the bound compounds can be achieved through the 
introduction of counter ions, which will compete for binding sites with the stationary 
phase, allowing for the compound to elute (123). Alternatively, the pH of the compound 
can be altered, which will affect its charge and thus will allow it to elute.  Ion-exchange 
chromatography utilizes two principals, either cation-exchange or anion exchange. When 
the compound of interest is positively charged, cation exchange is more appropriate to 
use, and it incorporates a negatively charged stationary phase. For negatively charged 
molecules such as peptides or proteins, anion-exchange resins are used. The positively 
charged stationary phase will bind to negatively charged moieties, until they are eluted 
using the aforementioned methods (123). While normal-phase refers to chromatography 
that utilizes a hydrophilic stationary phase, reverse-phase chromatography uses a column 
that is hydrophobic in nature, inverting the polarity of the stationary and mobile phases 
involved in the separation. The end result of reverse-phase chromatography is that more 
non-polar compounds will bind to the stationary phase through hydrophobic interactions. 
Elution of these compounds involves the use of an aqueous polar mobile phase, which is 
then made increasing nonpolar with a water miscible organic solvent. Separation based 
on polarity does not have to incorporate a mobile or stationary phase. Liquid-to-liquid 
extractions separate compounds based on polarity between an aqueous polar phase and 




typically moves from the aqueous phase to the organic phase through direct contact. 
After separation, the organic phase can then be further purified to isolate the now 
transferred compound (123). 
What follows covers the work regarding the partial isolation and characterization 
of an unknown, novel antibacterial produced by wild-type Burkholderia contaminans 
MS14. The efforts to isolate the bactericidal compound of MS14 utilized all of the 
particular separation methods described above. Crude extracts containing the 
bactericidal compound were used in these isolation methods. Crude antimicrobial 
extracts were derived from culturing MS14 in nutrient-rich media that was shown to 
yield bactericidal activity in deferred antagonism assays against primarily Gram-
negative organisms. From what has been learned in this study, the unknown compound 
is likely a novel antibiotic. For brevity, the unknown antimicrobial product being made 
by Burkholderia contaminans MS14 will be referred to as NAn-C (Novel Antibacterial 
Compound). 
 
3.3 Materials and methods 
3.3.1 Bacterial strains used and preparation of the crude extract containing bactericidal 
activity 
The wild-type B. contaminans MS14 strain was grown on modified NBY (487 
mL distilled water, 2.5 g peptone, 1.5 g Todd Hewitt, 1.0 g Yeast Extract, 1.0 g K2HPO4 
(anhydrous), 0.25 g KH2PO4, and 1.5% agar; 12.5 mL of 20% glucose and 0.5 mL of 1M 




overnight NBY agar plate were stabbed into 500 mL of modified NBY soft agar (NBY 
with only 0.75 % agar). The inoculum was incubated at 28 °C for 4 days, and then 
immediately frozen at -80 °C. The culture was then thawed in a 55 °C water bath for 1 h, 
then transferred to 250 mL centrifuge bottles and centrifuged at 20,000 x g for 30 
minutes. The collected supernatant was pooled, mixed with 1 gram of poly-aromatic 
absorbance resin Diaion HP-20 and shaken for one hour. The resin was allowed to settle 
before decanting the supernatant and was resuspended in 10 mL of 50% 
acetonitrile:water. The extract was dried by lyophilization and resuspended in 1 mL of 
35% acetonitrile:water. The extract was tested for antibacterial activity, as described 
below, before being used in subsequent extraction experiments. 
 
3.3.2 Procedure for overlay and chrome azurol S (CAS) bioassays 
The extracts were tested for siderophore and antibacterial activity, by spotting on 
a Chrome Azurol S (CAS) plate or on an NBY plate overlaid with Erwinia amylovora 
2029, respectively. These experiments also allowed a means to visualize separation 
efficiency between the antibacterial component and the siderophore ornibactin. CAS 
plates were prepared in accordance to the established protocol by Schwyn & Neilands 
(124, 125). Bioassay plates used in overlay assays were made using a suspension of E. 
amylovora 2029 in liquid NBY broth at an OD600 of 0.2. This suspension was added to 
molten NBY top (0.75%) agar (200 µL of bacterial suspension per 5 mL top agar), 




 To perform the assays, both the prepared CAS plates and E. amylovora 2029 
overlay plates were treated in the same manner: 10 µL of extract was spotted directly on 
the plate and allowed to air dry in a biosafety cabinet, and were incubated overnight at 
28 °C. The following day, the CAS plates were observed for signs of chelation indicated 
by a color shift from blue to yellow-orange in the location of the spot, and the E. 
amylovora plates were observed for antibacterial activity by measuring the zones of 
inhibition. 
 
3.3.3 HPLC, size exclusion, and anionic exchange isolation techniques for NAn-C 
RP-HPLC was done using a 4.6 × 250 mm C18 column (Grace-Vydac, catalog 
201TP54) on a Bio-Rad BioLogic F10 Duo Flow with Quad Tec UV-Vis Detector 
system. A 1:10 dilution of extract in 35% acetonitrile containing 0.1% TFA at a final 
volume of 1 mL was injected for each run. Fractions were separated using a thirty 
minute gradient of 90:10 water:acetonitrile:0.1% trifluoroacetic acid to 20:80 
water:acetonitrile:0.1% trifluoroacetic acid at a flowrate of 1 mL/minute.   
Size exclusion chromatography was performed using a sample of crude extract in 
35% acetonitrile:water.  The sample (1 mL) was loaded onto a 0.7 x 20 cm Flex-Column 
(Kimble-Chase) packed with Sephadex G-10 resin from GE Healthcare Life Sciences. A 
void volume of 3 mL was determined using Dextran Blue (Spectrum Chemicals) and 
collected in two separate 1.5 mL microcentrifuge tubes, with subsequent fractions 
collected in 1.5 mL microcentrifuge tubes at a volume of 1 mL for each fraction. Upon 




then reconstituted in 65:35 water:acetonitrile:0.1% trifluoroacetic acid. The reconstituted 
extracts were tested for siderophore and antibacterial activity, as well as the efficiency of 
separating the siderophore and bactericidal activity, by spotting 10 µL of the extract on a 
CAS plates or on an NBY plate overlaid with Erwinia amylovora 2029. 
Anionic exchange resin was subsequently used to isolate NAn-C. Several 1 mL 
fractions of the active crude extract was combined with 0.5 mL each of a 50% slurry of 
Amberlite IRA-410 chloride resin  (Dow Chemical/Sigma Aldrich) in separate 
microcentrifuge tubes, shaken for 60 minutes and then pipetted to new microcentrifuge 
tubes. To test for successful adsorption to the resin the extracts were tested for 
antibacterial activity by spotting 10 µL of the extract on an NBY plate overlaid with 
Erwinia amylovora 2029. The remaining Amberlite resins were then washed with 
different solutions: 2M NaCl, a pH 3 solution and a pH 5 solution. 
 
3.3.4 Dialysis of NAn-C and siderophore ornibactin 
A volume of 750 µL of new extract was pipetted into a Biotech cellulose ester 
(CE) dialysis cartridge (MWCO 500-1000 Daltons; Spectrum Chemical Mfg. Corp. New 
Brunswick, NJ; Product No. 888-10729). The cartridge was then placed in a beaker to 
float in 1 L of distilled water. The extract was allowed to dialyze for a total of 72 hours, 
while stirring. The extract was tested for siderophore and antibacterial activity, as well as 
separation efficiency, by spotting 10 µL of the extract on a Chrome azurol S (CAS) 
plates or on an NBY plate overlaid with Erwinia amylovora 2029. These tests were 




test for successful passage of the antibacterial product and to ensure it did not bind to the 
membrane, the entire volume of dialysate water was lyophilized and reconstituted in 750 
µl of 65:35 water acetonitrile:0.1% trifluoroacetic acid. This reconstituted dialysate was 
tested for siderophore and antibacterial activity, as well as separation efficiency, by 
spotting 10 µL of the extract on a CAS plates or on an NBY plate overlaid with Erwinia 
amylovora 2029. 
 
3.3.5 Isolation of the antibacterial product through Kupchan extraction 
Isolation of the antimicrobial product through Kupchan extraction followed a 
modified protocol for the isolation of malleilactone, as described by Biggens et al (121). 
The wild-type B. contaminans MS14 strain was grown in modified NBY (487 mL 
distilled water, 2.5 g peptone, 1.5 g Todd Hewitt, 1.0 g Yeast Extract, 1.0 g K2HPO4 
(anhydrous), and 0.25 g KH2PO4; 12.5 mL of 20% glucose and 0.5 mL of 1M MgSO4 
was added after autoclaving) overnight at 28°C. 10 mL was inoculated into each of six 
flasks of 1 L modified NBY incubated at 28°C, 200 rpm, for 48 hours. The 6 L culture 
was extracted twice with an equal volume of ethyl acetate and dried in vacuo. This crude 
ethyl acetate extract was initially partitioned using a modified Kupchan Scheme (Figure 
3.9). The extract was resuspended in 500 mL of 90% methanol and then extracted 4 
times with 500 mL of hexanes. The remaining methanolic mixture was diluted to 2 L of 
60% methanol, split into 1 L fractions and each liter was extracted 4 times with 1 L 
dichloromethane. All three fractions (hexanes, dichloromethane, & methanol) were dried 




dichloromethane fraction, however as it was uncertain if the antimicrobial product was 
malleilactone, all extracts (including the ethyl acetate extract) were resuspended in 5 mL 
of 35% acetonitrile:water. These extracts were tested for antibacterial activity by the 
overlay assay described above as was the aqueous phase that remained after each extract 
was similarly dried and resuspended. 
 
3.3.6 Biophysical characterization of the antibacterial product 
 The antibacterial product was tested for stability under high and low pH, high 
temperature, and direct UV exposure for two hours, with time points being taken at 15, 
30 ,60 and 120 minutes.  For the pH tests, the protocol from Ellis et. al was adapted 
(126). NAn-C extract was dried in separate 1.5-ml microcentrifuge tubes labelled pH 5 
to pH 9. The dried samples were resuspended in 1 ml of RPMI 1640 medium. Using 
stock solutions of 6 M HCl and 6 M NaOH, the pHs of the samples were adjusted 
accordingly, and then samples were left at room temperature for 2 h. At the 15, 30, 60 
and 120 minute time points, the pH were readjusted to pH 7.0 and bioassays were 
performed. To test heat stability, 500 µL of extract was mixed with 500 µL of distilled 
water in a 1.5 mL microcentrifuge tube and incubated in a 65 °C water bath. To expose a 
sample to UV light, 500 µL of extract was mixed with 500 µL of distilled water in a 1.5 
mL microcentrifuge tube, and allowed to rest on an ultraviolet light box (265 nm) used 
for viewing electrophoresis gels.  
 10 µL of all of these samples were taken at 15, 30, 60 and 120 minutes and 




described above. After allowing to air dry, the plate was then incubated overnight at 28 
°C and was checked for growth inhibition the following morning. 
 
3.4 Results 
3.4.1 Separation of ornibactin from the antibacterial product through HPLC 
At this stage in the discovery process, it was well established that the bactericidal 
activity was closely tied to the presence of ornibactin. Because ornibactin also has 
bioactivity in the form of bacteriostatic growth inhibition, it was important to separate 
the two compounds. Attempts to separate the two compounds by HPLC were 
unsuccessful. As described in the methods, NAn-C did not bind to the C18 resin and 
remained in the flowthrough fraction, indicating that NAn-C is a polar compound 
(Figure 3.2). We then turned to other separation methods. 
 
3.4.2 Separation of ornibactin from the antibacterial product through size-exclusion 
chromatography 
A column packed with Sephadex G-10 resin was used to separate the bactericidal 
NAn-C and bacteriostatic ornibactin products present in the crude extracts of B. 
contaminans MS14. In order to determine separation efficiency between these 
antibiotics, an overlay assay and an iron chelation assay was performed (Figure 3.3). 
Fractions spotted on a Chrome azurol S (CAS) plate will change from blue to a yellow-
orange color, if the fraction contains an iron chelator, such as ornibactin. By comparing 




plate, it did appear that a small amount of separation was achieved: ornibactin eluted 
slightly earlier than the bactericidal compound, with the majority of chelation occurring 
in fractions 5 and 6, while the major bactericidal activity was centered around fraction 7. 
Unfortunately, the fractions that contained the highest amount of bactericidal activity 
still eluted with ornibactin. With the commercially available size-exclusion resins I was 
unable to resolve NAn-C from ornibactin, so a new approach was used.  
 
3.4.3 Isolation of the antibacterial product through ion-exchange 
We next attempted to separate NAn-C and ornibactin by anion exchange 
chromatography. The initial results were promising. Upon exposure to the resin, the 
MS14 extract lost most of its bactericidal activity, indicating that NAn-C was 
successfully bound to the resin (Figure 3.4). The remaining activity in the extract 
appeared to be bacteriostatic in nature, as it did not yield a clear zone of inhibition. This 
suggests that ornibactin remained in the extract, or that the extract still contained a sub-
lethal concentration of NAn-C. Unfortunately, bactericidal activity could not be 
recovered from the resin even after exposure to elution buffers containing 2M NaCl or  
at pH 5.0 or pH 3.0.   
 
3.4.4 Separation of ornibactin from the antibacterial product through dialysis 
Although the previous attempt to separate NAn-C and ornibactin by size 
exclusion chromatography was unsuccessful, the results suggested that the bactericidal 




whether NAn-C could be separated from the other known antibacterial products.  Rather 
than using the standard dialysis tubing techinique a dialysis cassette was used because it 
allows for good flow of the dialysate through the double-sided membrane. Samples of 
the extract were taken from the cassette at T-0, T-24, T-48 and T-72 and plated in an 
overlay assay in order to determine when the bactericidal compound successfully 
dialyzed through the membrane. The samples were also plated on CAS plates to 
determine if ornibactin was retained in the cartridge or had dialyzed through the 
membrane. The bactericidal compound dialyzed within 24 hours, with only 
bacteriostatic activity remaining in the extract (Figure 3.5). While this would initially 
seem promising, ornibactin was also able to pass through the membrane in the same 
amount of time, enough to where partial bioactivity could be attributed to its presence. 
To test whether NAn-C passed through the dialysis membrane, the dialysate (500 mL 
water) was lyophilized and reconstituted with 35% ACN into an volume equal to the 
original volume of the extract placed into the cartridge. This sample was tested on an 
overlay assay and a clear bactericidal zone of inhibition was still present, indicating that 
the compound passed through the membrane and was not degraded or bound to the 
dialysis membrane. The results of the deferred antagonism assay also showed that 
ornibactin dialyzed at a slower rate than NAn-C indicating that NAn-C is likely smaller 
than ornibactin (737 Da), consistent with the results from the size-exclusion 
chromatography. However, because ornibactin dialyzed with NAn-C, this method was 





3.4.5 Isolation of the antibacterial product through Kupchan extraction 
Unpublished RNA-seq and site directed mutagenesis work from Dr. Shien Lu’s 
group supports NAn-C being a small polyketide product (Dr. Shien Lu, personal 
communication). The RNA Seq data from wild-type and NAn-C deficient strains of B. 
contaminans MS14 provided a means to predict the biosynthetic genes involved in the 
production of NAn-C. Site directed mutagenesis of two predicted polyketide synthetases 
within this gene cluster further confirmed the importance of these products for the 
synthesis of NAn-C (Figure 3.6).  The predicted biosynthetic gene cluster in B. 
contaminans MS14 has a 76% DNA identity to a MAL gene cluster in B. pseudomallei 
K96243, the biosynthetic gene cluster responsible for the synthesis of malleilactone 
(122). The authors suggested that the compound likely functions as a siderophore and it 
only has a demonstrated bacteriostatic property, suggesting that while NAn-C may be 
similar in structure there are differences that grants in bactericidal activity. Following the 
established Kupchan extraction protocol (121) that was also used for isolating 
malleilactone from spent Burkholderia media, attempts with MS14 spent media did not 
yield the same results. Using this protocol, B. contaminans MS14 spent medium was 
successively washed with non-polar solvents, which in the original protocol would result 
in the product of interest being isolated in the final wash of dichloromethane. However, 
the bioactivity attributed to NAn-C remained in the aqueous phase, with only minor 
biostatic activity appearing in the ethyl acetate wash (Figure 3.7). These results suggest 
that the NAn-C compound produced by MS14 is not the same compound as 




differences in sequence identity between the predicted biosynthetic gene cluster of NAn-
C and malleilactone contribute to differences in the final product being produced. 
Another key difference between malleilactone and the unknown product of MS14 is that 
malleilactone does not exhibit bactericidal activity, while NAn-C does.  
 
3.4.6 Biophysical characterization of the unpurified antibacterial product NAn-C 
Even without the successful purification of NAn-C, some of its properties could 
be elucidated. Aqueous extracts containing NAn-C were exposed to high and low pH, 
ultraviolet light, and high (65°C) temperature (Figure 3.8). Samples were taken after 15, 
30, 60 and 120 minutes and plated against the Gram-negative indicator strain, E. 
amylovora. After 2 hours of exposure to 65°C, the sample appeared to retain most of its 
inhibitory activity. It does appear that some activity was lost after two hours of exposure 
to high and low pH, while most of the activity was retained at 60 minutes. However, in 
the sample exposed to UV light, the bactericidal activity was lost in as little as 15 
minutes. Although some activity remained, complete loss of inhibitory activity occurred 
between 30 and 60 minutes of UV exposure. These results suggest that NAn-C is 
temperature and pH stable. However, the compound is UV sensitive. 
 
3.5 Discussion 
 Despite not being able to successfully isolate the antibacterial compound, NAn-
C, important information was learned. B. contaminans MS14 is producing a small 




Dr. Lu’s group. Size exclusion chromatography and dialysis studies performed indicates 
that this compound is likely smaller than ornibactin (737 Da). Based on information 
learned from the HPLC and Kupchan extraction approaches, the antibacterial compound 
is very polar. Additional biophysical characterization studies on NAn-C, suggests that it 
is stable at acidic and basic pH, and high temperature conditions, while being sensitive 
to UV exposure. The high polarity, small size, and UV light sensitivity, contributed to 
the difficulty in purifying the antibacterial compound.  
Because it is well established that MS14 produces the potent antifungal 
occidiofungin, effort was made to ensure that the bioactivity that was being observed 
was due to a new product, rather than a secondary level of activity resulting from the 
production of occidiofungin. To test this, additional deferred antagonism assays were 
performed on the Gram-negative bacterium, E. amylovora. In this assay, B. contaminans 
MS14 exhibits strong bactericidal activity when grown on complex, nutrient-rich media 
(data not shown). However, when plated on minimal media, no such activity was 
observed. The same deferred antagonism assays were performed using the fungus 
Geotrichum candidum. In these particular assays, fungicidal activity was present due to 
the production of occidiofungin only on the minimal media plates. The lack of 
antibacterial activity on minimal media plates demonstrates that, even though 
occidiofungin is produced by MS14, it has no activity against a Gram-negative indicator 
E. amylovora, and thus the bactericidal activity observed is probably due to the new 
product, NAn-C. From here the primary goal was to purify the bactericidal product or at 




mutant strain that could no longer make ornibactin was also unable to produce the 
bactericidal activity. Separating the bactericidal compound from ornibactin would 
support the notion that ornibactin is important for regulating the production of NAn-C 
and that it is not involved in the observed bactericidal activity.  
A PKS biosynthetic gene cluster was identified by Dr. Lu’s group (Dr. Lu, 
personal communication) and confirmed to be responsible for the observed bactericidal 
activity by mutagenesis and complementation studies. The predicted biosynthetic gene 
cluster is expected to make a small polyketide product. According to sequence identity, 
the small polyketide product is likely structurally similar to malleilactone (Figure 3.10). 
However, NAn-C probably contains UV sensitive conjugative double bonds and 
additional polar groups, which contribute to differences in NAn-C solubility and UV 
stability compared to malleilactone. Our data further supports that the biosynthetic gene 
cluster in MS14 is making a distinct, different compound from malleilactone, which is 
produced by B. pseudomallei K96243. 
While the isolation of NAn-C was unsuccessful, modifications to the previous 
methods might allow it to be isolated. In particular, the size exclusion chromatography 
could be attempted using a longer column. Additionally, a weaker ion-exchange resin 
could be employed, possibly allowing the compound to unbind from IRA-410. 
Regarding the HPLC an additional test could be performed on the flowthrough: although 
NAn-C did not bind ornibactin should have. Testing the flowthrough for the presence (or 






Utilizing NAn-C in future studies as a potential therapeutic is still possible. The 
groundwork has been laid for future researchers to continue the work to isolate and 
characterize the unknown compound. For B. contaminans MS14, the methods previously 
outlined for its cultivation are likely sufficient for producing amounts necessary for 
further study, with only the methods of isolation needing to be refined. With the benefit 
of data collected and hindsight, an aspect that cannot be overlooked is an issue with its 
initial extraction: by using a resin with hydrophobic properties in its initial extraction, 
it’s likely that much of the antibacterial compound remained in the aqueous supernatant 
of the initial cultures. It is possible that the amounts of NAn-C that were able to be 
observed after extraction with the HP-20 resin were found due to non-specific binding to 
the resin, or possibly paired with a separate compound that had no trouble binding. With 
all the new information learned about the NAn-C compound, some of the previous 
attempts to purify it can be used again, albeit with altered parameters that could lead to 
more successful isolation. For example, a weaker ion-exchange resin could be used. 
Alternatively, HPLC can be attempted again. If using reverse phase, the column can be 
used to remove impurities from the flowthrough in a rather quick protocol. There also is 
the option of utilizing normal-phase HPLC, which would allow the hydrophilic NAn-C 
to remain in the stationary phase. Currently, we do know more about the likely physical 








Figure 3.1: Bioassays showing antibacterial activity derived from B. contaminans 
MS14. A) A deferred antagonism assay using of B. contaminans MS14 against E. 
amylovora 2029. B) An overlay assay using B. contaminans MS14 media extracts 
against the indicator strain Erwinia amylovora. Bactericidal activity was confirmed by 
removing agar plugs within the zones of inhibition and plating them on fresh plates (data 








Figure 3.2: Retention of B. contaminans MS14 media extracts on reverse Phase C18 
HPLC column. A) Chromatogram of a reverse phase HPLC using a gradient of 95-20 % 
water +0.1% trifluoracetic acid, on a 4.6 x 250 mm Agilent C-18 column. Starting with 
the flowthrough fraction (demarcated with an arrow), fractions were collected in 1 
minute intervals. B) Overlay assay of B. contaminans MS14 extract (blue circle) and the 
HPLC fractions against indicator strain Erwinia amylovora. The HPLC flowthrough (red 
circle) is the only fraction that retained the inhibitory activity. The blue circle 





Figure 3.3: Size-exclusion chromatography (Sephadex G-10) of B. contaminans MS14 
media extracts.  A) B. contaminans MS14 extract was loaded onto column and 1 ml 
samples were collected following the determined void volume. Sample fractions were 
tested for inhibitory activity using an overlay assay against E. amylovora. B) B. 
contaminans MS14 extract was loaded onto column and 0.5 ml samples were collected 
following the determined void volume.  Sample fractions were tested for inhibitory 
activity using an overlay assay against E. amylovora. C) The same 0.5 ml sample 
fractions from plate B were additionally tested for siderophore activity on a chrome 
azurol S plate. Note that all the fractions that demonstrated bioactivity has strong iron 
chelation present in the corresponding fractions on the CAS plate, indicating the 







Figure 3.4: NAn-C extraction and isolation attempt using Amberlite IRA-410 Resin. A) 
1mL of B. contaminans MS14 extract was combined with 0.5 mL slurry of Amberlite 
IRA-410, an anion exchange resin, and vigorously agitated for an hour. 10 uL of both 
the original and the Amberlite-exposed extract were tested against the indicator strain E. 
amylovora in an overlay assay. B) Attempts to extract the bactericidal compound from 
the Amberlite resin included washes with 2M NaCl, a pH3 and a pH5 buffer wash. 
These washes were tested for activity against the indicator bacterium E. amylovora in an 











Figure 3.5: Dialysis of B. contaminans MS14 extract. A) B. contaminans MS14 extract 
was dialyzed using a CE cartridge (MWCO 500-1000 Da) for 72 hours in distilled water. 
At the 24, 48, and 72-hour time points, 10uL of the extract was withdrawn from the 
cartridge and stored to be tested later against the indicator bacterium E. amylovora in an 
overlay assay. Although bactericidal activity is observed at T-0, loss of bactericidal 
activity was observed at 24 hours, indicating that all of the bactericidal compound 
passed through the dialyzing membrane. The bacteriostatic activity of ornibactin is able 
to be observed at all time points. B) CAS plate corresponding to samples shown in 
image A showed that ornibactin diffused much slower across the membrane than NAn-
C. Siderophore activity was still present in the 72-hour extract sample. C) After 72 hours 
of dialysis, the distilled water dialysate was lyophilized and reconstituted to a volume 
equal to the original dialyzed extract, then tested against the indicator bacterium E. 
amylovora in an overlay assay. Bactericidal activity was observed, indicating that NAn-
C was successfully recovered. This indicates that the compound did not bind to the 







Figure 3.6: A: The 36 Kbp MS14 polyketide biosynthesis gene cluster. B: CRISPR-
Cas9 mutagenesis sequence analysis at the targeting site of the gene NL30_RS36215 in 
the MT215C, MT215C-5, and MT215C-6 mutant strains. The figure was provided by 







Figure 3.7: Kupchan extraction of NAn-C in the MS14 extract. A) Liquid to liquid 
extractions of cell-free B. contaminans MS14 spent media were performed following the 
protocol for malleilactone purification. In each extraction, successive washes of the 
aqueous extract phase were performed with non-polar solvents, in descending order. 
Following the extractions, all phases were evaporated/lyophilized and concentrated and 
tested for bactericidal activity against the indicator bacterium E. amylovora in an overlay 
assay.  When compared to the original extract, all bactericidal activity remained in the 







Figure 3.8: NAn-C stability assays using the MS14 extract. A) B. contaminans MS14 
extract was exposed to acidic, basic, direct UV and 65°C conditions for two hours, with 
time points collected after 15, 30, 60 and 120 minutes and tested against the indicator 
bacterium E. amylovora in an overlay assay. Antibacterial activity was able to be 
observed in all samples tested, barring the sample exposed to ultraviolet light, which had 
attenuated activity after only 15 minutes. Complete loss of activity for this sample 
occurred somewhere between 30 to 60 minutes of exposure. Activity was persistent in 
all other variables tested, indicating that the NAn-C product of MS14 is highly stable in 







Figure 3.9: Diagram representing the modified Kupchan extraction. This protocol was 
adapted from the method used to extract malleilactone from B. pseudomallei. In the 
original protocol, malleilactone was found in the dichloromethane fraction, and it was 





























The studies outlined in this thesis have highlighted the potential of the 
Burkholderia genus for the discovery of novel antimicrobial compounds.  My thesis 
highlights the potential of Burkholderia contaminans MS14 to make novel antimicrobial 
metabolites, i.e. occidiofungins, ornibactin, and a novel bactericidal compound (NAn-C). 
There is a need for new treatment options as the ever-increasing prevalence of antibiotic-
resistant pathogens, coupled with the declining rate of discovery for new antibiotic 
treatment options, could lead to a global crisis if not addressed. Further studies in this 
interesting genus could potentially lead to the development of novel therapeutics for 
treating infectious diseases. 
Antibiotic resistant pathogens represent a substantial threat to nations worldwide, 
imposing loss of life, human suffering, and a drain of healthcare resources due to 
increased treatment cost and extended recovery times (2, 127). Antibiotic resistance also 
impairs the ability of agricultural systems to respond to blights amongst crops and 
outbreaks in livestock populations, posing a threat to regional and potentially global food 
supply lines. Due to the perceived high risk of investment into antibiotic research, 
investment into novel antibiotics by the world’s largest pharmaceutical companies has 
fallen dramatically since its peak in the late 1980’s; in 2020, only 1 of the 35 companies 
conducting research in antibiotic clinical development ranked among the top 50 
pharmaceutical companies by sales (128). The need for novel antibiotics and funding for 




Organization for Animal Health, Food and Agriculture Organization of the United 
Nations, and the Organization for Economic Co-operation and Development in their 
joint report filed in 2017 (129, 130). If the discovery rate of novel antibiotics does not 
rebound, the impact of antibiotic resistance will continue to grow. 
The use of bacterial and fungal-sourced medicines extends back to antiquity, 
however mass production of antibiotics from natural sources for commercial medicinal 
use is a concept that only goes back to the 20th century. These sources have brought 
civilization-changing medicines, with many treatments still prescribed today, such as the 
glycopeptide vancomycin, the macrolide erythromycin, or the most well-known beta-
lactam antibiotic, penicillin. However, for every new antibiotic that makes it to clinical 
use, there are countless other that do not. The complications that arise with discovering 
new natural drug products are multi-faceted and are present at every stage of 
development. For example, identifying and locating producing species, establishing 
efficient culturing and purification procedures, and learning the spectrum of activity or 
mechanism of action can take several years to complete. Furthermore, identifying lead 
candidates for animal efficacy and toxicological studies often leads to the understanding 
of drug limitations. These studies further lead to efforts at synthesizing novel and more 
effective analogs and specialized formulations. Despite all of the knowledge and tools 
currently available for research, 1 in 5 drugs that make it into clinical trials still fail FDA 
approval. This is why it is crucial to identify potentially useful reservoirs of novel 
products that could have clinical implications and the Burkholderia genus appears to be 




With regards to antimicrobial production, Burkholderia contaminans MS14 is 
one of the most well studied strains of Burkholderia. Occidiofungin, which is produced 
by this strain, has been shown to be a potential therapeutic for fungal and parasitic 
infections (131), as well as having potent activity against several cancer cell lines (132). 
Several naturally occurring variants of occidiofungin are produced by the bacterium. 
Interestingly, the biosynthesis of occidiofungin involves two distinct thioesterases that 
lead to the formation of conformationally distinct products (133). Additional studies are 
needed to determine the differences and potential application that these naturally 
occurring analogs of occidiofungin for the treatment of infectious diseases and cancer. 
This stain also has a demonstrated bactericidal activity, in which the compound for the 
activity remains unknown. Remarkably, a novel function for a siderophore has been 
characterized in this strain. It has been shown to be essential for the production of an 
unknown polyketide antibiotic, suggesting that the siderophore is involved in the 
regulation of the product and not just being important for iron sequestration (36).     
With the highly conserved genome amongst the Burkholderia genus, 
observations gleaned from one species can likely be applied to other species within the 
genus. There is evidence to support that secondary metabolite production can be 
impeded with slight manipulation to the host environment (36), suggesting that virulence 
factors in other more infectious species may also be attenuated in this manner. A better 
understanding of the environmental factors leading to the regulation of possible 
virulence factors may likely be learned from studying gene regulation within avirulent 




to the Pseudomonas genus and techniques learned could be applied to its species as well, 
such as Pseudomonas aeruginosa, the primary colonizer of cystic fibrosis patients (19). 
With the rate of multi-drug resistant infections increasing, and the decrease in 
new antibiotic discovery, a more detailed examination of the members within the 
Burkholderia genus is more important than ever. Despite having two members tied to 
infectious diseases, many ot the hundreds more have been shown to have beneficial 
effects with growth promotion in crops, or be strong candidates for further studies aimed 
at isolating and characterizing the products being made. One of the larger challenges is 
overcoming the stigma associated with the more virulent members of the genus, as this 
causes some trepidation with regards to its widespread study. However, with new 
avenues needed for novel therapeutics, it is inevitable that Burkholderia genus will be 
studied more thoroughly. If successful, additional efforts studying Burkholderia could 
lead to the development of new antifungals and antibacterials for treating medically 
relevant infectious diseases. Further, the wide spread use of Burkholderia species may 
find its most promising use in promoting a sustainable food supply. The prevention of 
plant diseases caused by fungal diseases, bacterial diseases, and pathogenic nematodes 
may be accomplished by using tailored strains of Burkholderia. The genus requires 
additional attention towards identifying novel metabolites and research efforts aimed 
toward understanding their application for plant and human diseases.   
 My work has laid the foundation for future studies that could lead to new insights 
into novel therapeutics: there is a new potent antibacterial present in the production of 




and its subsequent elimination when ornibactin production is halted, opens up the 
question if other secondary metabolites can be manipulated in a similar manner. 
Specifically, the question remains if these concepts can be applied to virulence factors of 
other species that also rely on ornibactin as it is shown to have a role beyond iron-
sequestration. The possibility of using a novel approach such as this to attenuate 
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